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1. I N T R O D U C T I O N
Diabetic retinopathy is the major ocular
complication of diabetes, both in terms of incidence
and irreversible visual impairment. In spite of modern
procedures for strict blood glucose control (DCCT,
1993), laser treatment (ETDRS, 1991f; Aiello, 1994),
vitrectomy (Gardner and Blankenship, 1994; Glaser,
1994b), and classical pituitary ablation (Kohner et
al., 1976; Speakman et al., 1966; Poulsen, 1953), it
is a serious threat to normal vision. It is mainly a
vascular disorder, primarily involving microvessels
(Garner, 1970). Retinal capillaries undergo multiple,
extremely complex structural alterations in response
to the unavoidable hyperglycemia of long-term
diabetes. Because many of the angiopathies occur on
microscopic vessels before retinal changes can be
detected clinically, differentiating primary from
secondary events in the etiology of diabetic
retinopathy has been difficult. Histopathological
studies are critical for determining the earliest
microscopic changes that may cause the subsequent,
clinically discernable, constellation of lesions
comprising this disorder. Identification of the

primary, triggering factors and the development of
an appropriate animal model are necessary for the
design and evaluation of therapies to prevent the
m a n y debilitating effects of this diabetic
complication.
A summary of the salient clinical and
histopathological features of diabetic retinopathy is
presented first (Sections 2 - 5 ) to provide a basis for
subsequent discussions of experimental models
(Sections 6 and 7), currently available therapeutics
(Sections 8-10), possible underlying mechanisms
(Sections 11 and 12) and the significance of the
galactose-fed rat model (Section 13). There has been
a deliberate attempt to keep Sections 2 - 5 free of any
reference to animal data so that the true status of
current information on the human condition can be
evaluated as accurately and independently as possible
before assessing the relevancy of animal models.
Emphasis throughout will be placed on the initial
pathologies and their possible prevention or delay.
There is evidence that the primary triggering event
of diabetic retinopathy is the increase in tissue aldose
reductase activity, which results from elevated
circulating levels of glucose and other hexoses. The

595

Aldose Reductase and Diabetic Retinopathy
reduction of excess glucose results in marked
intracellular accumulation of sorbitol and unleashes a
cascade of biochemical and structural anomalies.
Clear causative relationships have been demonstrated
between increased aldose reductase activity and the
earliest structural changes of diabetic retinopathy:
capillary basement membrane thickening and
intramural pericyte loss. These, in turn, are probably
causally linked to various subsequent retinal microangiopathies such as endothelial cell proliferation,
microaneurysms, dilated channels and overt
neovascularization.

2. DIABETIC RETINOPATHY: INCIDENCE
AND C L I N I C A L CHARACTERISTICS

Diabetic retinopathy is the main cause of blindness
by a single systemic disease in Great Britain (Garner,
1970) and the leading cause of blindness in the
United States in 20-74 yr-old individuals (Klein et
aL, 1984a,b; Klein and Klein, 1985). The majority of
individuals who have had diabetes mellitus for > 15

yr have developed some clinically visible signs of
diabetic retinopathy: approximately 98% if they
became diabetic before reaching 30 yr of age (Klein
et al., 1984a) and 78% if they became diabetic after
reaching 30 yr of age (Klein et al., 1984b). After 15
yr of Type I diabetes, 50% of the subjects have
proliferative retinopathy (Klein et al., 1984a).
Blindness is 25-29 times more common in diabetic
than in non-diabetic individuals (Fong and Rand,
1994; Klein and Klein, 1985). It was estimated almost
two decades ago (National Advisory Eye Council,
1977) that 300,000 people in the United States were
at risk of blindness from diabetic retinopathy.
Because the prevalence of diabetes continues to
increase (Warram et al., 1994), the number of people
at risk is also increasing, perhaps now approaching
500,000. Since insulin was introduced as a
therapeutic agent for systemic diabetes mellitus
(Banting and Best, 1922), many lives have been
saved, but the incidence of diabetic complications
has risen, especially for complications that usually
take several years to develop, as does diabetic
retinopathy (Klein and Klein, 1985; Krolewski et al.,
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1987; White, 1960). Whereas diabetes accounted for
only 1.0% of new blindness in the United States in
1930, it was responsible for 15% by 1960 (Winter,
1960).
Although some neurological changes occur
(Bresnick et al., 1984), vascular pathology, primarily
involving the retinal microvessels (capillaries)
constitutes the main component of diabetic
retinopathy (Cogan and Kuwabara, 1967a,b; Deruaz,
1969; de Venecia et al., 1976; Garner, 1970).
Blindness (defined as a best-corrected vision of
20/200 or worse) results from one of the following,
all of which are indicative of compromised vessels:
(1) macular edema - - when the increased
permeability of damaged intraretinal vessels
contributes to severe thickening at the center of the
macula; (2) non-resolving vitreous hemorrhage - when new, pre-retinal and intravitreal vessels rupture;
(3) traction retinal detachment - - when the
fibrovascular proliferations and associated vitreous
elements undergo sufficient contraction and/or
displacement to detach the retina (Aiello, 1994;
Davis, 1988; ETDRS, 1991d; Patz and Fine, 1977).
The spectrum of retinal angiopathies that precedes
these final conditions is very broad (Fig. 1; Sections
5 and 11), involving not only a constellation of
capillary lesions, which are probably primary, but
changes in arterioles, venules and various rheological
parameters of the retinal circulation (Ashton, 1983;
Cogan et al., 1961; Cunha-Vaz, 1991; ETDRS,
1991a,d,f; Garner, 1970, 1993).
Most of the clinical signs and potential diagnostic
characteristics of diabetic retinopathy were described
in the 19th century, though not fully linked to diabetes
(James, 1980). Ophthalmoscopically, no particular
sequence of changes occurs consistently.
Nevertheless, usually the first clinical manifestation
of diabetic retinopathy is the appearance of one or
more small, often clustered, microaneurysms usually
limited to the posterior pole. The posterior pole is
defined as the central retina surrounding the optic
disc and including, roughly, the area enclosed by the
superior and inferior temporal vessels (Cogan, 1974).
Moderate dilations of veins may accompany or
precede microaneurysm detection (L'Esperance,
1989). Frequently, small 'dot and blot' hemorrhages
are intercalated between the microaneurysms and can
be indistinguishable from them. Another relatively
early change observed by central fundus examination

is the appearance of white to yellowish spots with
rather distinct borders in the deep retinal layers.
These so-called hard exudates consist of concentrated
derivatives of plasma that escaped from the
compromised vessels (Garner, 1994). They are found
most frequently in association with macular edema,
microaneurysms and other microangiopathies. A
more advanced condition is marked by the formation
of various intraretinal microvascular abnormalities,
or IRMA (Section 5.6), which may be difficult to
distinguish from intravitreal neovascularization. They
represent irregular focal dilations and varicosities of
capillaries, which have become large enough to be
resolved ophthalmoscopically. IRMA are most
clearly visible when they occur in the middle of the
capillary plexus, where all other vessels (capillaries)
are too small to be detected by fundus exam. Here
they appear as isolated islands of enlarged, tortuous
vascular segments ranging in size from barely visible
to 30 txm or more in diameter. Cotton-wool spots
(sometimes called soft exudates) occur only in the
superficial layer of the retina. They are indicative of
nerve damage resulting from ischemic conditions
(Section 5.7). While their presence suggests
advancing diabetic angiopathy, their severity is a
relatively weak predictor of retinopathy progression
(ETDRS, 1991d,f). They can occur at any time, even
with relatively mild retinopathy (Brown et al., 1985;
Kohner et al., 1969). Venous beading and macular
edema are almost always associated with the severe
non-proliferative stage. Although perivenous
sheathing, perivenous exudates and arteriovenous
nicking are minor lesions with respect to the
frequency of their occurrence, they are included in
the grading systems used in clinical trials (DRS,
1981b).
The proliferative stage of diabetic retinopathy is
the most threatening with respect to the potential for
causing severe loss of vision (ETDRS, 1991d,f). The
new vessels usually arise on the surface of the optic
disc or from veins near arteriovenous crossings
(Michaelson, 1948; Taylor and Dobree, 1970). The
areas of proliferation are often associated with regions
of ischemia (Garner, 1994). The new vessels may
grow directly into the vitreous or remain at least
temporarily between the inner limiting membrane
and the retina. Extraretinal neovascularization is
usually followed soon by pre-retinal hemorrhages
and fibrous proliferations, which form pre-retinal
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membranes. Repeated hemorrhaging, retinal edema
and/or retinal detachment may lead to irreversible
visual loss.

3. CLASSIFICATION AND GRADING OF
MAIN FUNDUS CHANGES
Classification systems of the clinically discernable
retinal lesions are similar in complexity to the lesions
themselves. Attempts to assign angiopathies to stages
or use quantitative grading systems to assess the
severity of diabetic retinopathy have undergone
continual updating. Often, two broad categories have
been utilized - - background and proliferative
diabetic retinopathy (Garner, 1994; L'Esperance,
1989). Occasionally a pre-proliferative division has
been added between the two (Benson et al., 1988;
DRS, 1978; Sahel et al., 1994). However, many
refinements have been developed as more precise
information has become available and as
modifications have been needed to meet the
requirements of particular investigations (DRS, 1976,
1978, 1981a,b; ETDRS, 1991c,d,f; Goldberg and
Fine, 1969; L'Esperance, 1989). Now, essentially all
grading systems utilize a set of standard fundus
photographs to make precise and reproducible
assessments (DRS, 1981a,b; ETDRS, 1991d,f). The
lesions have been subdivided and grouped based on
how predictive they are of the proliferative stage and
ultimate blindness (Aiello, 1994; ETDRS, 1991d,f).
As a result, each category contains eyes with similar
prognoses, and there is an orderly progression of risk
with increasing category (ETDRS, 19910.
The findings that have emerged from the grading
efforts tend to confirm early notions that the different
retinal microangiopathies form a continuum: one
stage ordinarily leading to another, after having arisen
from a previous stage (L'Esperance, 1989). This
assumption is generally accepted with the caveat that
some patients may never develop more than nonproliferative retinopathy. The current systems (Aiello,
1994; ETDRS, 1991a,d,f; L'Esperance, 1989)
classify the lesions into mild, moderate, severe and
very severe stages of non-proliferative diabetic
retinopathy and mild, moderate and high-risk stages
of proliferative diabetic retinopathy. Modified
classification systems have been developed to utilize
information gained from retinal fluorescein
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angiography (ETDRS, 1991e,g). Although not
utilized for diagnosis, a pre-retinopathy stage was
proposed to accommodate evidence of some early
retinal lesions, including vessel leakage, which are
observed by vitreous fluorophotometry to occur
before angiopathies are detectable by fundus
photography or fluorescein angiography (Cunha-Vaz
et al., 1975).
There are marked changes in blood components
and flow characteristics in diabetes (Feke et al.,
1994; Frank, 1994; Hatchell and Sinclair, 1994;
Little, 1976), but none has yet been utilized in
standardized classification systems (Aiello et al.,
1985; ETDRS, 1991b).

4. ROLE OF TECHNOLOGICAL
DEVELOPMENTS IN CORRELATING
HISTOPATHOLOGIES
Advancements in technological procedures have
had a major impact on all aspects of investigation on
the nature
of diabetes-related
retinal
microangiopathies. Microaneurysms were first
described in 1877 by Nettleship in making a
pathological report on a case for MacKenzie and
were definitively associated with diabetes soon after
(James, 1980). However, their rediscovery as an
important entity in pathological material was delayed
until the 1940s. By then, techniques of fundus
photography (Bedell, 1939; James, 1980) and
specialized procedures for vessel staining and
injection with contrast media followed by
examination of flat retinal whole mounts permitted
histopathological correlations. These demonstrated
that microaneurysms and minute, perfectly round
hemorrhages are among the earliest changes of
diabetic retinopathy (Ballantyne, 1945; Ballantyne
and Loewenstein, 1944; Friedenwald, 1949, 1950;
Ashton, 1949, 1950).
The important role of pericytes in early
microangiopathy (Kuwabara and Cogan, 1963; Cogan
and Kuwabara, 1967a) was not recognized until
improved histopathological procedures (Kuwabara
and Cogan, 1960) permitted enzyme digestion and
removal of essentially all non-vascular tissues,
leaving relatively intact vascular beds, which could
be mounted and stained. Although various enzyme
combinations were used including pepsin plus trypsin
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Table 1. Spectrum of Retinal Microangiopathies in Diabetic Retinopathy Compared to Other

Disorders
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and collagenase plus trypsin (Addison e t a l . , 1970;
Ashton, 1963; Ashton and Tripathi, 1975), use of the
crude pancreatic trypsin extract originally reported
(Kuwabara and Cogan, 1960) became standard in
most ocular pathology laboratories for the next 30 yr.
Recently, Laver e t al. (1993) demonstrated that the
most important component of the crude trypsin
extract is elastase and that purified elastase alone in
appropriate buffers provides cleaner preparations and
more consistent results. The elastase digestion
procedure permits the isolation of intact vascular
beds from retinas previously resistant to processing
owing to extraordinary vessel fragility.

5. U N I Q U E N E S S O F L E S I O N S T O D I A B E T I C
RETINOPATHY
Two histopathological lesions are essentially
unique to diabetic retinopathy, and several others
occur as a characteristic group of lesions, which
itself forms a unique spectrum (Aiello, 1994; Benson
e t a l . , 1988; Cogan and Kuwabara, 1967b; Garner,
1993). The two unique lesions - - (1) a diffuse
thickening of capillary basement membranes
superimposed on age-related thickening; and (2) a
selective loss of intramural pericytes - - are not only
unique in their occurrence, but they are the two
earliest lesions to occur in diabetic retinopathy
(Addison e t a L , 1970; Ashton, 1974; Bloodworth,
1967; Cogan and Kuwabara, 1967a; Kuwabara and
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Cogan, 1963; Sahel e t a l . , 1994; Speiser e t a l . ,
1968; Yanoff, 1966). All subsequent lesions may
occur in various other retinopathies, but even so,
they usually are not expressed in the same way and
are not accompanied by many of the other lesions of
the typical 'diabetic retinopathy spectrum' (Table 1).
Subsequent to capillary basement membrane
thickening and selective pericyte loss, the most
important histopathological lesions have been
identified as the following: (1) endothelial
proliferation; (2) capillary microaneurysms; and (3)
capillary closure (Ashton, 1963). These correlate
well with the five basic clinical pathological
processes: (1) capillary occlusion; (2) permeability;
(3) microaneurysms; (4) vessel-glial proliferation;
and (5) glial-vitreal contraction (Aiello e t a l . , 1985;
Davis, 1988). Table 1 summarizes the salient
histopathological and clinical lesions that form the
spectrum of retinal microangiopathies characteristic
of diabetic retinopathy and indicates their occurrence
and relative similarities in other retinal
vasculopathies. It is clear that no other ocular or
systemic disorder exhibits the same spectrum of
retinal lesions in the same way as does diabetic
retinopathy. No other disorder shows such a close
association in the posterior pole among retinal areas
of p e r i c y t e loss, n o n - p e r f u s i o n , punctate
microaneurysms, 'dot and blot' hemorrhages, hard
exudates, cotton-wool spots and IRMA (Cogan and
Kuwabara, 1967b; Benson e t a l . , 1988). Figure 1
shows the probable sequences and inter-relationships

Table 1 (continued)
1. Ashton (1974); 2. Ashton (1983); 3. Bloodworth (1962); 4. Bloodworth (1963); 5. Bloodworth
(1967); 6. Green et al. (1980); 7. Sugi (1966); 8. Section 5.1; Archer et al. (1991); 10. Ashton (1971); 11.
Cogan and Kuwabara(1967a); 12. Garner (1970); 13. Speiser et al. (1968); 14. Yanoff (1966); 15. Archer
(1976); 16. Ashton (1963); 17. Benson et al. (1988); 18. Cogan et al. (1961); 19. Kohner and Henkind
(1970); 20. Palmer et aL (1994); 21. Weinberg and Seddon (1994); 22. Wise (1957); 23. Section 5.2; 24.
Brown and Benson (1984); 25. Chaudhuri et al. (1981); 26. Hayreh (1970); 27. Garner (1994); 28. Keith
et al. (1939); 29. Maguire and Schachat (1994); 30. Yanko et al. (1975); 31. Section 5.3; 32. Ashton
(1950); 33. Ashton (1959); 34. Bresnick et al. (1976); 35. Bresnick (1994); 36. Brown et al. (1985); 37.
Cogan and Kuwabara (1967b); 38. de Venetia et al. (1976); 39. Goldberg (1976); 40. Shimizu et al.
(1981); 41. Toussaint (1968); 42. Section 5.4; 43. Section 11; 44. Ashton (1949); 45. Ballantyne (1945);
46. Brown (1994a, 1994b); 47. Cogan (1974); 48. Duke et al. (1968); 49. Kuwabara et al. (1961); 50.
Michaelson (1980); 51. Section 5.5; 52. Section 5.6; 53. Ashton and Harry (1963); 54. Kohner and Doilery
(1969); 55. Kohner et al. (1969); 56. Mansour et al. (1990a); 57. Section 5.7; 58. Archer (1977); 59. Patz
(1984); 60. Section 5.8; 61. Section 5.9.
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of microangiopathies in the etiology of diabetic
retinopathy.

5.1. Capillary Basement Membrane Thickening
and Selective Pericyte Loss
A marked, diffuse thickening of the basement
membranes which ensheathe capillaries is a hallmark
of diabetic microangiopathy (Ashton, 1974, 1983;
Williamson and Kilo, 1977). The basement
membranes form a thin covering around the
endothelial tube and completely envelop the
intramural pericytes in capillaries of essentially all
body tissues. A progressive, diffuse thickening also
occurs with the normal aging process (Table 1), but
it does not develop as rapidly or to the same extent
as in diabetes. Whereas the basement membranes of
retinal capillaries are normally approximately 80-120
nm in thickness, they may become 3-5 times thicker
in diabetic compared to non-diabetic subjects of
comparable ages (Ashton, 1974, 1983; Bloodworth,
1962, 1963, 1967; Toussaint and Dustin, 1963). The
basement membrane thickening reported in other
disorders is either focal rather than diffuse or only
involves larger than capillary size vessels. Qualitative
changes also occur in basement membrane
components, but few analytical studies are available
(Carlson, 1989; Carlson and Bjork, 1990; Toussaint
and Dustin, 1963).
There is no firm evidence for a selective loss of
capillary pericytes in any condition other than
diabetic retinopathy (Table 1). Normal aging may
involve a selective loss of capillary endothelial cells
(Kuwabara et al., 1961) or loss of both pericytes and
endothelial cells, equally, but not a loss of pericytes
alone. Sugi (1966) using data obtained from 170
autopsy eyes of non-diabetic individuals with various
other diseases or advanced age alone demonstrated
significant loss of capillary cells, but no preferential
loss of pericytes. Cogan and Kuwabara (1967a)
clearly demonstrated degeneration of pericytes in
retinal digests of autopsy eyes from diabetic patients
by excellent micrographs of intramural pockets
('ghosts') lacking stainable nuclei in capillaries with
normally stained endothelial cell nuclei. They also
reported that non-diabetic humans have
approximately a 1:1 ratio of pericytes to endothelial
cells whereas in diabetic persons the ratio decreases
to 1:4, suggesting a selective loss of pericytes. These

pioneer findings were confirmed and systematically
documented in several subsequent studies of trypsin
digest preparations. Sugi (1966) documented a loss
of capillary cells in eight out of nine diabetic retinas:
of which, four exhibited loss of both endothelial cells
and pericytes and another four had a greater loss of
pericytes than endothelial cells. Yanoff (1966)
reported retinal pericyte to endothelial cell ratios
ranging from 1:1.0 to 1:1.2 in 11 autopsy eyes
representing various diseases, including renal failure
(uremia), compared to ratios of 1:1.5 to 1:18.3 in 11
diabetic eyes. He found that the extent of decreased
pericyte to endothelial cell ratio correlated directly
with numbers of microaneurysms. Speiser et al.
(1968) analyzed 209 autopsy eyes: 46 of which were
from diabetic persons, 126 from patients with various
chronic disorders and 37 from individuals dying of
non-disease-related causes. A statistically significant
difference ( p = 0.0001) was found in mean ratios of
endothelial cells to pericytes in non-diabetic persons
free of other diseases (1.1, range 0.52-1.56)
compared to diabetic patients (5.2, range 0.6217.54), indicating a selective loss of pericytes. The
ratios for persons with other diseases ranged from
1.3 to 1.8. These investigators also provided evidence
that there was no increase in the number of
endothelial cells p e r capillary length, thus
demonstrating that the change in ratio did indeed
result from a selective loss of pericytes.
In spite of a few reports to the contrary (de
Oliveira, 1966), early supernormal thickening of
capillary basement membrane and selective loss of
intramural pericytes are considered hallmarks of
diabetic microangiopathy and unique to diabetic
retinopathy (Ashton, 1983; Bloodworth, 1967; Cogan
and Kuwabara, 1967a; Deruaz, 1969; Speiser et al.,
1968; Sugi, 1966; Toussaint and Dustin, 1963;
Williamson and Kilo, 1977; Yanoff, 1966). Even so,
identification of the earliest time when these lesions
occur or which of the two lesions occurs first in
human diabetic retinopathy has never been
determined unequivocally. Both pericyte loss and
capillary basement membrane thickening are
microscopic changes that develop during the
clinically silent phase. They do not match the criteria
for the pre-retinopathy stage, which has been utilized
by Cunha-Vaz (1991) for functional lesions. Whether
they should be assigned to a new, 'microscopic
stage' remains to be determined.
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5.2. Dilations and Endothelial Cell Hypertrophy
A moderate, uniform dilation of all the capillaries
of the plexus occurs during the early stages of
diabetic retinopathy (Cogan, 1974). Later, many
varicosities and extraordinarily large dilations
develop in localized regions, accompanied by
endothelial cell hypertrophy. Many of the larger
dilations form hyperceUular channels that traverse
large acellular areas of the plexus. Others develop as
'islands' isolated in the middle of capillary beds
where they must depend on much smaller capillaries
for perfusion (Kohner and Henkind, 1970; Section
5.6). The cell proliferation involved has been
considered to be an expression of intraretinal
neovascularization involved in microaneurysm and
IRMA formation (Kohner and Henkind, 1970; Wise,
1957). Commonly in diabetes, but only rarely in
other diseases (Table 1), capillaries that have
undergone endothelial cell hypertrophy, capillary
dilation and varicose transformations are found sideby-side with non-perfused capillaries.

5.3. Permeability and Hard Exudates
The hard exudates, observed ophthalmoscopically
as white to yellowish spots, indicate plasma leakage
from compromised vessels. These exudates are
aggregations of lipoprotein, cholesterol crystals and
foamy histiocytes (Garner, 1994). Their
topographical association with microaneurysms,
capillary dilations and acellular capillaries in the
posterior pole is characteristic of diabetic retinopathy
(Table 1). Although the exudates of radiation
retinopathy are very similar, they differ in that they
are associated with disc edema.

5.4. Capillary Non-perfusion, Occlusion and
Acellularity
Capillary non-perfusion resulting from occlusion
and associated with aceUularity is a prominent feature
and is also considered a hallmark of diabetic
retinopathy (Ashton, 1963; Benson et al., 1988;
Bresnick, 1994; Bresnick et al., 1976; Garner, 1994).
Retinal areas of capillary occlusion were first

601

demonstrated by India ink injections of autopsy
specimens (Ashton, 1950) and were later associated
topographically with the areas of acellularity
observed histopathologically (Cogan and Kuwabara,
1967b; Kuwabara and Cogan, 1965) and with the
areas of non-perfusion observed clinically (de
Venecia et al., 1976; Kohner and Henkind, 1970;
Bresnick et al., 1976). In diabetes, unlike most other
disorders (Table 1), capillary non-perfusion is
characteristically confined to the posterior pole and
closely associated topographically with
microaneurysms, dilated hypercellular capillaries,
IRMA, hard exudates and cotton-wool spots (Ashton,
1959; Cogan and Kuwabara, 1967b; Cogan et al.,
1961; Kohner and Henkind, 1970; Toussaint, 1968).

5.5. Microaneurysms
Hemorrhages

and

Intraretinal

Small, 'dot and blot' intraretinal hemorrhages and
microaneurysms are usually the first funduscopic
signs of diabetic retinopathy (Ballantyne and
Loewenstein, 1944; Davis, 1988; Michaelson, 1980;
ETDRS, 1991d,f). Although they are barely
distinguishable clinically, they are very distinct in
structure when examined in histological sections.
Many of the entities originally interpreted clinically
to be small, well-defined hemorrhages ('dot and blot'
type) were revealed to be microaneurysms by
histopathological exam (Ashton, 1949). Clinically,
microaneurysms are the main hallmark of diabetic
retinopathy (Table 1), although they do occur in
other diseases and tissues (Garner, 1994).
Examination of retinal digest preparations permits
identification of occluded as well as patent
microaneurysms. Summarizing their numerous
histopathological studies of diabetic retinopathy
Cogan and Kuwabara (1967b, p. 61) stated that
"...microaneurysms are much more numerous than
would have been suspected clinically."

5.6. Irma, Shunts
Meshworks

and

Dilated

Capillary

Intraretinal microvascular abnormalities (IRMA)
originated as a clinical term although the
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histopathological correlates had already been
documented using various names for the individual
components (Bloodworth, 1967; Cogan and
Kuwabara, 1963; Cogan et al., 1961; Kohner and
Henkind, 1970; Toussaint, 1968). IRMA were
defined as: "...the abnormal vascular structures
within the retina variously interpreted as 'shunt'
vessels, dilated pre-existing capillaries, fusiform
aneurysms, or intraretinal neovascularization" (Davis
et al., 1969, p. 13). Transections of IRMA
demonstrate a wide variety of changes that capillaries
are capable of undergoing. The extent of capillary
dilation, shape change and wall abnormality is truly
extraordinary. The dilations can be greater than 10fold and involve several capillary branches. The
dilations can give rise to the formation of minute or
large fusiform bulges, sausage-shaped varicosities,
loops, complex coils, channels and networks, by
various distortions of capillary walls (Cogan et al.,
1961; de Venecia et aL, 1976; Wise, 1957). IRMA
are not limited to diabetic retinopathy, but tend to be
most prominent in this disorder as it develops to the
severe non-proliferative stage (Table 1).

Dollery, 1969; Kohner et al., 1969) or may not
(Michaelson, 1980) be preceded by capillary dilations
and occlusions. Though not permanent, cotton-wool
spots persist for relatively long periods in diabetes,
having half-lives of 8.1-17.2 months (Kohner et al.,
1969), compared to an average disappearance time of
6.9 weeks in the acquired immunodeficiency
syndrome (Mansour et al., 1990a). Their expressions
in other disorders are noted in Table 1.

5.8. Extraretinai Vessei-Glial Proliferation

The neovascularization on the surface of the retina
and/or optic disc is a hallmark of proliferative
diabetic retinopathy (Davis, 1988). The new vessels
arise from the venous circulation (Norton and
Gutman, 1967) and are accompanied by development
of fibrotic tissue, which becomes permanently
connected to the strands of vitreal collagen and plays
an important role in subsequent events. There is
nothing completely specific about the process, but in
other disorders it is not accompanied by the other
lesions typical of diabetes and it is less likely to be
limited to the posterior pole (Table 1).

5.7. Cotton-Wool Spots and Ischemia

The cotton-wool spot (sometimes called soft
exudate) is located in the nerve fiber cell layer. It is
not an exudate at all: histologically, the cotton-wool
spot is composed of an aggregate of several spherical
to oblong bodies called cytoid bodies due to their
resemblance to cells (Ashton and Harry, 1963;
Garner, 1994; Wolter, 1959). By electron
microscopy, each cytoid body was shown to contain
accumulations of remnant debris from degenerated
axoplasmic organelles including mitochondria,
endoplasmic reticulum and nenrofilaments (Ashton,
1970). The cytoid body probably results from
obstruction of orthograde or retrograde axoplasmic
transport (McLeod et al., 1977) and swelling with
accumulation of cell organelles in a disrupted
ganglion cell axon. Clinically, the cotton-wool spot
is indicative of regions of non-perfusion and
ischemia, often associated with arteriole occlusion
(Destro and Gragoudas, 1994; Garner, 1994; Kohner
and Dollery, 1969). Its development may be preceded
by arteriolar occlusion, which may (Kohner and

5.9. Extraretinal Hemorrhages, Glial-Vitreal
Contraction and Macular Edema

These three processes, any of which is capable of
precipitating irreversible blindness in diabetic patients
(Benson et al., 1988; Patz and Fine, 1977), differ
little in their expression in other severe retinal
vascular disorders. They are probably a general
expression of a highly damaged and traumatized
retina.

6. EXPERIMENTAL MODELS OF DIABETIC
RETINOPATHY
The importance of animal models for studies of
diabetic retinopathy cannot be overstated. Unless
adequate amounts of tissue with detailed records are
available, the correct timing and inter-relationships
of etiological events as well as the causative factors
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cannot be determined. Retinal biopsies from diabetic
patients are not feasible. Presently, donor eyes from
diabetic patients have become more available, but
their usefulness is limited. The clinical histories are
often incomplete and the variables introduced by
postmortem autolytic processes are hard to minimize.
Only appropriate animal models permit the collection
and proper preservation of adequate amounts of tissue
under experimentally-controlled conditions.
Until recently, experimental studies on the basic
mechanisms underlying the complete spectrum of
angiopathies of diabetic retinopathy, and the testing
of potential therapeutic agents have been severely
hampered by the lack of reliable and convenient
animal models (Engerman et al., 1982; Robison and
Laver, 1993). Many animal models are available for
diabetes as a systemic disease (Karasik and Hattori,
1994; Shafrir, 1993), but the same cannot be said for
diabetic retinopathy, which is not the disease itself,
but one of its many complications. In fact,
investigators who have evaluated many animal
models of diabetes as a systemic disease have drawn
attention to the striking lack of adequate models of
diabetic retinopathy (Engerman et al., 1982; Patz
and Maumenee, 1962). Some promising models are
now emerging. These will be discussed here, whereas
human disorders and animal systems that provide
insight into certain elements of diabetic retinal
angiopathies will be covered in Section 11.

6.1. Diabetic Rodents

Theoretically, strains of laboratory mice and rats
should provide ideal sources for models of both
systemic diabetes and its tissue complications,
whether studying hereditary or induced diabetes. The
genetic homogeneity, economy and handling
conveniences are very favorable. There are, in fact,
numerous mouse and rat models of systemic diabetes
mellitus, and other rodent models are continually
being defined (Cohen and Rosenmann, ~1990; Doi et
al., 1990; Karasik and Hattori, 1994; Michaelis et
al., 1988; Mori et aL, 1991; Shafrir, 1993), including
the recently developed transgenic mouse models for
studies of tissue-specific aspects of diabetes (Erickson
et aL, 1990; Lee and Sarvetnick, 1993; Lutty et al.,
1994; Stewart et al., 1993).
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However, the same is not true for diabetic
complications. Neither the mouse nor the rat, whether
its diabetes is hereditary or induced, has provided a
completely satisfactory model for the entire set of
diabetes-related retinal vascular complications of
long-term hyperglycemia in man (Engerman et al.,
1982; Robison et al., 1991b). Several types of
diabetic rats are good models for diabetic cataracts
and diabetic keratopathy (Kinoshita and Nishimura,
1988; Kinoshita et al., 1990; Robison and Laver,
1993), but they usually only manifest some of the
early lesions of diabetic retinopathy, such as capillary
basement membrane thickening, intramural pericyte
degeneration, endothelial cell proliferation and
acellularity (Kern and Engerman, 1994;
Papachristodoulou and Heath, 1977; Robison et al.,
1991b; Sima et al., 1983, 1985). They rarely exhibit
microaneurysms (Agrawal et al., 1966; BootHandford and Heath, 1980; Cohen et al., 1972;
Cohen and Rosenmann, 1990; Engerman et al., 1982;
Papachristodoulou et al., 1976; Robison et al.,
1991b; Rosenmann et al., 1975; Yanko et al., 1971,
1975). Except for rare reports such as that by
Toussaint (1968), they have not been demonstrated
to develop IRMA or proliferative retinopathy
(Engerman et al., 1982; Kern and Engerman, 1994;
Robison et al., 1991b; Cohen and Rosenmann, 1990).
Significant thickening of retinal capillary
basement membrane has been reported in
streptozotocin-induced diabetic rats by several
investigators: Fischer and Giirtner (1983) after 12
months of hyperglycemia; Tilton et al. (1986) after
6-9 months; McCaleb et al. (1991) after 6-8 months;
and Kojima et al. (1985) by as early as 3 months.
Pericyte ghosts have been documented in
micrographs by several investigators in both retinal
digests and electron micrographs (Chakrabarti et al.,
1987; Robison et al., 1991b). Pericyte ghosts,
endothelial cell proliferation, capillary acellularity
and varicose loops were documented in three different
rat models with 6-8-month durations of diabetes
(Robison et al., 1991b). Two were models for Type
I diabetes: one by inheritance (BB Wistar diabetic);
the other by streptozotocin injection (45 mg/kg).
The third was a model for Type II diabetes
(SHR/N-cp
diabetic rat). No microaneurysms,
IRMA or more advanced lesions were found.
Probably the relatively short life-spans of diabetic
rats and/or their spontaneous reversion to euglyremia
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(Kern and Engerman, 1994) preclude the
development of lesions of the severe non-proliferative
or proliferative stages of diabetic retinopathy. Such
lesions are slow to develop, taking a minimum of 4
yr and often taking more than 10 yr in humans
(Krolewski et al., 1987). This would explain why
only the early lesions, such as capillary basement
membrane thickening and pericyte degeneration,
occur consistently in diabetic rats.

6.2. Diabetic Cats

The domestic cat has a retinal vascular pattern
very similar to humans, but only a few reports of
diabetic retinopathy in cats have appeared (Gepts
and Toussaint, 1967; Toussaint, 1968; Mansour et
al., 1990b). Gepts and Toussaint (1967) studied five
spontaneously diabetic cats, some of which had
documented durations as long as 7 months. They
found that some had pericyte ghosts, focal
acellularity, and/or varicose capillaries. Although
many attempts to induce diabetes in cats have failed,
diabetes can be achieved by procedures involving
partial pancreatectomy alone or in combination with
local injections of alloxan into the artery supplying
the remaining pancreas (Mansour et al., 1990b;
Reiser et al., 1987). In cats rendered diabetic by
such methods, Mansour et al. (1990b) documented a
significant increase in retinal capillary basement
membrane thickness following 3-10 months of
diabetes. Hatchell et al. (1994a) reported
hemorrhages, microaneurysms, non-perfusion and
IRMA as early as 7.5 yr in diabetic cats followed for
9 yr. Funduscopic examination was facilitated since
cats do not develop diabetic cataracts.

6.3. Diabetic Non-human Primates

Non-human primates should be good models for
diabetic retinopathy because their retinas have a
fovea and a pattern of vascularization and capillary
structure almost indistinguishable from that of human
retinas. However, developing diabetic retinal
microangiopathies in monkeys on a consistent basis
has been difficult. In spite of the many approaches
which have been used to induce diabetes, retinal
lesions have been observed only rarely, even after 10

yr of diabetes, and the results are inconsistent (Frank,
1994). There is no clear documentation of pericyte
loss or basement membrane thickening. Jonasson et
al. (1985) found only the mild non-proliferative stage
of diabetic retinopathy in a large series of monkeys
with up to 12 yr of streptozotocin-induced diabetes.
Microaneurysms have been reported occasionally,
but seldom with supporting micrographs (Bresnick
et al., 1976; Danis and Wallow, 1986; Gibbs et al.,
1969). Several investigators have expressed their
frustrations with the difficulty of inducing diabetic
retinopathy in non-human primates. Nevertheless,
recent preliminary results (Laver et al., 1994) suggest
that a spontaneously diabetic monkey colony
described and maintained by Hansen et al. (1991,
1994) may provide a source of meaningful models
for several diabetic retinal microangiopathies
characteristic of the non-proliferative stages. A
classical Type II non-insulin dependent diabetes
mellitus develops in middle-aged rhesus monkeys of
this colony. After diabetes durations of 1-8 yr, these
monkeys had varied amounts of pericyte
degeneration, statistically significant thickening of
retinal capillary basement membranes, capillary
dilation, acellularity, occlusion, endothelial cell
proliferation and a few microaneurysms (Laver et
al., 1994). Because of the potential importance of a
reliable non-human primate model for diabetic
retinopathy, such leads merit further investigation.

6.4. Diabetic Dogs

A spontaneously diabetic dog was the first
experimental model of a near complete spectrum of
angiopathies characteristic of diabetic retinopathy
(Patz and Maumenee, 1962). Its discovery dispelled
the concept which had been developing for some
time that diabetic retinopathy might be a diabetic
vascular complication unique to human diabetes. A
dog that had spontaneous diabetes for approximately
3 yr demonstrated pericyte degeneration with ghost
formation, microaneurysms, acellularity, endothelial
cell proliferation and putative exudates, along with
cataracts and kidney lesions. Apparently, some
microaneurysms exhibited loss of pericytes and
proliferation of endothelial cells, while others
demonstrated hyalinization (Patz and Maumenee,
1962). No IRMA or proliferative retinopathy
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developed. Later, Patz et al. (1965) reported several
early lesions of non-proliferative retinopathy in seven
out of 12 spontaneously diabetic dogs. Engerman
and Bloodworth (1965) reported non-proliferative
retinopathy in two out of five dogs with
metasomatotropin-induced diabetes and in one out of
five with alloxan-induced diabetes. They added
intraretinal hemorrhage to the list of the lesions of
non-proliferative retinopathy which can be produced
in diabetic dogs. Although not identified as such by
them, their so-called 'oversize hypercellular
capillary' could be classified as IRMA because of its
size and large, irregular branches. Although retinas
were examined histologically after 9, 15, 34, 37, 41,
43, 53, 67 and 69 months of diabetes, only those
from the three dogs with durations of more than 43
months developed the retinal microangiopathies.
Gepts and Toussaint (1967) reported typical nonproliferative diabetic retinal microangiopathies in 22
out of 30 diabetic dogs. The microangiopathies
included pericyte ghosts, focal loss of endothelial
cells as well as pericytes, generalized acellularity of
capillaries, irregularly-dilated (varicose) capillaries,
and typical microaneurysms. Sibay and Hausler
(1967) documented saccular microaneurysms and
hypercellular dilated capillaries, which could be
classified as IRMA, in a dog that was diabetic for 5
yr, while only dilated capillaries were observed in a
dog that was diabetic for 2 yr. Several additional
studies (Bloodworth, 1967; Bloodworth and Molitor,
1965; Engerman et al., 1977; Toussaint, 1968) have
confirmed the validity of the diabetic dog as a model
of diabetic cataracts and essentially all the nonproliferative stages of diabetic retinopathy. However,
in all these studies, microangiopathies required 48-60
months to develop, and proliferative stages have
never been reported. Identification of the earliest
retinal lesions in diabetic dogs has not been
determined. Although some evidence suggests
capillary basement membrane thickening and pericyte
loss occur early (Stitt et al., 1994), just when they
happen and which takes place first is not established.

6.5. Galactose-fed Dogs and Rats
A more complete diabetic-like spectrum of retinal
microangiopathies can be induced in non-diabetic
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dogs and rats fed a galactose diet than has been
reported in any other animal model (Engerman and
Kern, 1984; Frank et al., 1983; Kador, 1990; Kador
et al., 1988, 1990, 1994; Robison et al., 1983, 1986,
1988, 1989a, 1990c, 1991a; Robison and Laver,
1993; Takahashi et al., 1992). This discovery has
not only provided a great asset to research on diabetic
retinopathy, but it offers insight into the underlying
mechanism of diabetic retinopathy. Galactose-fed
animals have normal plasma glucose levels, but they
share an important abnormality with diabetic humans.
They accumulate high tissue levels of polyol
(Sections 12.4 and 13.2), indicative of increased
aldose reductase activity, which has been implicated
in many diabetic complications (Dvornik, 1987;
Frank, 1994; Fukushi et al., 1980; Gonzfilez et al.,
1984; Kinoshita and Nishimura, 1988; Nishimura et
a/., 1988a). So, while galactose-fed animals would
not be expected to manifest the full complement of
physiological changes characteristic of diabetes, they
would be expected to develop aldose reductaserelated tissue complications. In fact, the
complications should generally occur sooner and/or
be more severe since aldose reductase has a higher
affinity for galactose than for glucose (Hayman and
Kinoshita, 1965), resulting in more polyol synthesis
under hypergalactosemic than hyperglycemic
conditions. Also, unlike sorbitol, galactitol is not
metabolized by the cell, so polyol accumulates more
rapidly (Fig. 2) and reaches much higher levels in
tissues of galactose-fed animals than diabetic animals
(Dvornik, 1987; Dvornik et al., 1988, 1994; Stewart
et al., 1968; Section 12.4). As expected, polyolrelated tissue complications such as cataracts and
keratopathy do, indeed, occur sooner in galactose-fed
animals (Dvornik, 1987; Kinoshita and Nishimura,
1988; Robison et aL, 1990a; Robison and Laver,
1993). Sugar cataracts develop in galactose-fed rats
in 2-3 weeks compared to 2-3 months in diabetic
rats (Fukushi et al., 1980; Hu et al., 1983). The rate
of cataract development is directly related to the per
cent of dietary galactose, severity of galactosemia
and lens polyol accumulation in galactose-fed rats
(Dvornik, 1987; Simard-Duquesne and Dvornik,
1973; Simard-Duquesne et al., 1985).
Based on its potential for accelerating the
development of aldose reductase-related diabetic
complications, galaetose was fed to animals with the
hope that diabetes-related retinal microangiopathies
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would also occur sooner. The positive results
obtained suggested that diabetic retinopathy, like
cataracts, is also a tissue complication related to
aldose reductase activity. Not only dogs fed 30%
galactose (Engerman and Kern, 1984; Kador, 1990;
Kador et al., 1988, 1990, 1994), but also rats fed
either 30 or 50% galactose (Frank et al., 1983; Kern
and Engerman, 1995; Robison et al., 1983, 1986,
1989a, 1990c, 1991a; Robison and Laver, 1993;
Laver and Robison, 1993) responded to elevated
tissue polyol levels by developing diabetic-like retinal
lesions (Section 7).

(A)

7. SIMILAR/TIES BETWEEN GALACTOSE
MODELS AND HUMAN DIABETIC
RETINOPATHY
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Although the retinas of dogs and rats have no
fovea and their major vessels form unique arrays,
their capillaries are similar in diameter, meshwork
patterns and ultrastructure to human retinal capillaries
(Figs 3-5). As in human diabetes, the capillaries of
the posterior, central retina were the first structures
to show signs of retinopathy in galactose-fed animals
(K_ador et al., 1990; Robison et al., 1991a; Robison
and Laver, 1993; Takahashi et al., 1992). The types
of microangiopathies and the sequence patterns,
which developed through the high-risk proliferative
stage in the dog and the mild proliferative stage in
the rat, were extraordinarily similar to those of
diabetic retinopathy in humans.
As in diabetic patients, the earliest
histopathological retinal lesions (Figs 4 and 5) are a
diffuse thickening of capillary basement membranes
and degeneration of the intramural capillary pericytes
of the central retina (Robison et al., 1983, 1986,
1988, 1989a, 1990c; Robison and Nagata, 1988;
Robison and Laver, 1993; Kador, 1990; Kador et al.,
1988, 1990; Takahashi et al., 1992). The earliest
significant increase in retinal capillary basement
membrane thickness has not been clearly documented
in humans or these animal models. Previously, it was
reported to occur as early as 7 months in rats fed
50% galactose (Robison et al., 1983, 1986), but is
now known to take place as early as 6 months (Fig.
5; Robison et al., 1993). As in humans (Carlson,
1989; Carlson and Bjork, 1990; Toussaint and Dustin,
1963), there are qualitative as well as quantitative
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Fig. 2. Rapid tissue polyol accumulation in lens epithelium.
A, Sorbitol in rats rendered diabetic by streptozotocin injection [ - - - non-diabetic (n = 3); - - * - diabetic (n = 6);
--O-diabetic plus AL-1576 (n = 6); ~
non-diabetic plus AL-1576 (n = 1)]. B, Galactitol in rats fed a 30%
galactose diet [ ...... non-galactosemic (n -- 3); - - < > - - galactosemic (n = 6); - - 0 - galactosemic plus AL-1576 (n ffi
6); and m __ __ non-galactosemic plus AL-1576 (n = 1)].
The aldose reductase inhibitor, AL-1576 (4 m g / k g / d a y ,
was administered every 24 hr by garage.

changes in capillary basement membranes in
galactose-fed animals. The thickened basement
membranes have a greater tendency to become
multilaminar and vacuolated as well as acquire
various electron-opaque inclusions such as fibrous
collagen and degenerated pedcyte remnants (Frank
et al., 1983; Robison et al., 1983, 1986, 1988).
When the pericytes degenerate, they leave
empty-appearing pockets in the ensheathing basement
membranes, often called pericyte 'ghosts' (Figs 4
and 5). Pericyte ghosts first appear in galactose-fed
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Fig. 3. Similarity of microvessels in human and rat retinas. Retinal vessels from a rat (A) fed 50% galaetose for 6 months
beginning at weaning; and from an 86-yr-old diabetic person (B). All arteries (A), veins (V) and capillaries (C) appeared
normal at this magnification. Note the typical avascular zone of the macular (M) region in the human. PAS/hematoxylin stain.
Both calibration bars represent 500 p.m. Reproduced from Robison and Laver (1993) by permission and courtesy of
Smith-Gordon and Co. Ltd.
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Fig. 4. Intramural pericyte loss in human retinal capillaries. A, Light micrograph of capillaries from the perimacular region of
Fig. 3B, showing intramural perieyte ghosts (pg) and nuclei of normal endothelial cells (e) and pericytes (p). B, Electron
micrograph of a capillary from a similar region of the companion eye, Showing a normal red blood cell (rbc), lumen (L) and
endothelial cell lining (e), but abnormally thickened basement membrane (bin) and degenerated cytoplasmic remnants in all the
intramural pericyte compartments (pg). The calibration bars represent 10 and 1.0 ~m, respectively.
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dogs after 19 months (Kador et al., 1988) and in
galactose-fed rats after 6 months or less (Fig. 5). In
humans, the first appearance of pericyte ghosts has
not been determined with certainty (Section 5.1), but
it occurs before clinical signs of retinopathy (Figs 3B

and 4). The possible mechanisms of pericyte
its relation to subsequent clinical lesions
discussed in Section 12.4.
In galactose-fed animal models, as in
there are two different ways that capillaries
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Fig. 5. Intramural pericyte loss in rat retinal capillaries. Retinal capillaries from rats fed 50% galactose for 6 months beginning
at weaning showing, by light microscopywith PAS/hematoxylin stain, A, an intramural pericyte ghost (pg), without a nucleus,
as well as endothelial cells (e) and pericytes (p) with normal nuclei; and, by electron microscopy,B, a capillary with a normal
lumen (L) and endothelial cell lining (e), but abnormally thickened basement membrane (bm) and degenerated cytoplasmic
remnants representing pericyte ghost (pg) cytoplasm in all the intramural pericyte compartments. The calibration bars represent
10 and 1.0 ixm, respectively.
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Fig. 6. Diabetes-related microangiopathies in rats and humans. Retinal vessels from a rat fed 50% galactose for 24 months
beginning at weaning, A, and from a 62-yr-old diabetic person who had utilized insulin for 15 yr, B. In both cases, many
microaneurysms (ma) and acellular capillaries (ac) are present and some of the smaller arteries (A) and veins (V) have become
tortuous. However, the most striking changes, when compared to the normal appearing structures observed in Fig. 3, are
capillaries that have become irregularly dilated to extraordinary diameters to form tortuous, hypercellular channels and dilated
meshworks (din and arrowheads). PAS/hematoxylin stain. Both calibration bars represent 500 ~m.
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Fig. 7. Diabetes-related microangiopathies in rats and humans. Retinal vessels from a rat fed 50% galactose for 24 months
beginning at weaning, A, and from a 58-yr-oid diabetic individual who had utilized insulin for more than 13 yr, B. In both
cases, intramural pericyte ghosts (pg), lightly-stained acellular capillaries (ac) and darkly-stained, apparently occluded
capillaries (oc) are present. However, the most striking changes, when compared to the normal appearing structures seen in Fig.
3, are capillaries which have become irregularly dilated (de) to extraordinary diameters to form cylindrical microaneurysms
(cm), tortuous, hyperceUular channels and dilated meshworks (din) in association with both arteries (A) and veins (V) and
accompanied by perivascular glial proliferations. PAS/hematoxylin stain. Both calibration bars represent 50 i~m.
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Fig. 8. Types of microaneurysms in rat retinas. Retinal vessels from rats fed 50% galactose for 24 months, showing several
types of microaneurysms (ma), including saccular, A, fusiform with hyalinization, B, cylindrical, C, and irregular, D. The
microaneurysms are accompanied by dilated capillaries (dc), capillaries with pericyte ghosts (pg) and acellular capillaries (ac),
many of which appear to be occluded (oc), as judged by their degree of PAS staining. The microaneurysms can occur near the
middle of the capillary plexus or in close association with arteries or veins (V). PAS/hematoxylin stain. The calibration bar
represents 30 ~m for all micrographs.
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to pericyte loss. Some capillaries, in which pericytes
have degenerated, exhibit a proliferation of
endothelial cells and dilate to several times their
original diameters, thus approaching the diameters of
the major retinal vessels (Kador et al., 1990; Robison
et aL, 1989a, 1991a, Robison and Laver, 1993).
Focal dilations result in microaneurysms, whereas
more extensive dilations create hypercellular
channels, shunts and other IRMA, some of which
form dilated meshwork patterns (Cogan and
Kuwabara, 1963; Cogan et al., 1961). By contrast,
other capillaries, which are often adjacent, respond
in an essentially opposite way. Instead of dilating,
these capillaries maintain a normal diameter and lose
their endothelial cells as well as their pericytes. As in
humans (Ashton, 1983; Kuwabara and Cogan, 1965),
such capillaries become acellular, non-functional and
eventually are filled with glial cell cytoplasm
(Robison and Laver, 1993; Robison et al., 1990c).
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The areas of acellularity occur mainly in the central
retina and are often closely associated with
hypercellular channels, microaneurysms and IRMA
(Figs 6 and 7) - - a pattern very characteristic of
human diabetic retinopathy.
Microaneurysm formation in the polyol-induced
retinopathy of dogs and rats appears to be very
similar to that in human diabetic retinopathy.
Microaneurysms form by 27 months in galactose-fed
dogs and as early as 16 months in galactose-fed rats.
The types of microaneurysms include saccular,
fusiform, cylindrical (tubular) and irregularly-shaped
as well as many aggregations of the same (Fig. 8).
Some are hyalinized, but most are patent. These
exhibit the characteristic microaneurysm structure in
transection, having an endothelial cell lining devoid
of pericytes as in humans (Yanoff, 1969), and a
lumen filled with erythrocytes (Fig. 9). Saccular
microaneurysms are often observed in galactose-fed

Fig. 9. Patent microaneurysm in a rat retina. Retinal micrograph from a rat fed 50% galactose for 28 months showing a
transected microaneurysm(ma) in the inner nuclear layer (INL) with red blood cells (arrows) in the lumen and an endothelial
cell lining (en) devoid of pericytes. The microaneurysmhas a diameter far exceeding the normal diameter (arrowhead) of
vessels in the inner nuclear layer, and is accompaniedby a partially disrupted outer nuclear layer (ONL) with many surviving
rod (m) and cone (cn) nuclei. The calibration bar represents 25 p~m.Reproducedfrom Kinoshita et al. (1990).
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rats (Fig. 8A), but occur less frequently in rats than
in dogs or humans (Robison et al., 1989a; Robison
and Laver, 1993). The cylindrical microneurysms are
often associated with perivascular glial proliferation
(Fig. 7).
Capillary dilations that involve longer segments
have been variously called tubular microaneurysms,
hypercellular channels (Kohner and Henkind, 1970)
or capillary ensheathing (Cogan et al., 1961) in
descriptions of human diabetic retinopathy. Similar
structures occur in both galactose-fed dogs and rats
(Kador et al., 1990; Robison et al., 1989a, 1991a;
Robison and Laver, 1993). When the hypercellular
channels involve relatively extensive capillary
segments and include several branches and
anastomoses in the plexus network (Figs 6 and 7),
they have been called dilated meshworks (Robison
et al., 1989a). All these anomalies are the histological
correlates of the clinically visible group of lesions
called IRMA, which probably involve intraretinal
neovascularization (de Venecia et al., 1976) and
may act as shunts (preferential channels). In humans,
they are characteristic of the severe non-proliferative
stage of diabetic retinopathy and are highly predictive
of proliferative retinopathy (Davis, 1991). In
galactose-fed rats, IRMA are more prominent than
microaneurysms in that they occur more frequently
and involve more of the total capillary length.
'Dot and blot' hemorrhages occur by 33 months
in galactose-fed dogs and can be observed clinically.
In galactose-fed rats, hemorrhages occur by 24
months, but histological sections are required for
their demonstration because the galactose-induced
lens opacity is greater in rats. Likewise, hard exudates
and cotton-wool spots occur in galactose-fed rats as
well as dogs, but in rats they canbe observed only in
sectioned retinas. As in humans, veins become dilated
and tortuous in galactose-fed rats (Fig. 6; Robison et
al., 1989a).
Recently, extraretinal neovascularizations were
documented in galactose-fed dogs after 72 months
(Kador et al., 1994; Takahashi et al., 1992) and
galactose-fed rats after 24-28 months (Laver and
Robison, 1993), suggesting even greater similarity
with humans and usefulness of these models of
diabetic retinopathy. As in humans, the new vessels
tend to develop first on or surrounding the optic disc.
It is noteworthy that the regular occurrence of
diabetic-like retinal microangiopathies through the

severe non-proliferative stage in galactose-fed rats
has been confirmed by a completely independent
laboratory (Section 13.5).
As described (Sections 5 and 11), a specific
spectrum of lesions is considered to be unique to
human diabetic retinopathy. Although any one of the
typical microangiopathies or some combination may
occur in certain other retinal dysfunctions (Table 1)
and some experimental models (Section 6), until
now, the complete combination and pattern of lesions
had not been demonstrated in any animal model.
Presently, the entire spectrum of human-like diabetic
retinal angiopathies can be produced on a regular
basis in both galactose-fed dogs and rats, two very
distinct animal models.
Besides diabetic retinopathy, the retinopathy that
most closely simulates the spectrum of lesions found
in the galactose-fed dog and galactose-fed rat models
is radiation retinopathy (Table 1; Sections 5 and 11).
Radiation retinopathy occurs when patients receive a
total dose of 6000 rads or more (Archer et aL, 1991;
Chaudhuri et al., 1981; Hayreh, 1970; Maguire and
Schachat, 1994). Like diabetic retinopathy, radiation
retinopathy has a silent phase between the initial
insult and the clinical expression of retinal
microangiopathies, but this is significantly shorter.
The latent period usually extends from 18 months to
3 yr following radiation treatment. Like diabetic
retinopathy, radiation retinopathy is mainly a vascular
disease involving microaneurysms, intraretinal
hemorrhages (mainly superficial), telangiectases, hard
exudates, cotton-wool spots, macular edema,
capillary non-perfusion, neovascularization, vitreal
hemorrhages and retinal detachment. However,
radiation retinopathy differs from diabetic retinopathy
in that it has fewer microaneurysms, and there is a
selective loss of capillary endothelial cells rather
than pericytes. Although basement membrane
thickening occurs, it only affects vessels larger than
capillaries (Chaudhuri et al., 1981). The galactosefed animals experienced no radiation, and their early
selective loss of pericytes, capillary basement
membrane thickening, and frequent microaneurysm
formation, best match the microangiopathies
observed in human diabetic retinopathy.
Both the galactose-fed dog and the galactose-fed
rat have distinct advantages over genetic or
chemically-induced models of human diabetic
retinopathy. The changes induced by galactose

Aldose Reductaseand Diabetic Retinopathy
feeding are more advanced and more like human
diabetic lesions than those which develop in longterm diabetic animals. Not only do galactose-fed
animals demonstrate lesions earlier, but they are
otherwise more healthy and have normal life-spans.
Proliferative retinopathy has not been reported in
diabetic dogs or rats. Diabetic rats usually do not live
long enough to demonstrate more than capillary
basement membrane thickening and pericyte loss
(Robison et al., 1991b). By contrast, galactose-fed
animals can develop retinopathy through the
proliferative stages (Kador et al., 1994; Laver and
Robison, 1993; Robison and Laver, 1993).
Galactose-fed animals can be taken off the diet and
returned to a normal physiological state within a few
days. Thus, the effectiveness of intervening with
therapeutic agents can be compared with complete
removal of the physiological insult. This approach is
not completely matched in any other animal model.
The dog and rat models provide unique
contributions for particular studies. The galactose-fed
dog permits clinical monitoring of the progression of
diabetic retinopathy by ophthalmoscopic examination
whereas the rat does not. Although cataracts are
induced by galactose feeding in both models, some
visualization of the fundus is still possible in the dog
model since incomplete lens opacity and lens
resorption are common in the dog, but not in the rat.
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Alternatively, the rat develops retinopathy sooner,
and is more practical and economical to maintain as
well as handle. The fact that clinical evaluation is
unfeasible in the rat is partially compensated by the
potential for greater availability of necropsy material,
owing to the larger numbers of rats, which can be
utilized within given limits of space and funds.
Galactose-fed animal models and diabetic humans
have two important features in common: (1) their
abnormal accumulations of tissue polyol and (2)
their extraordinarily similar patterns of retinal
microangiopathies. This commonality plus the
majority of other evidences suggest that the reduction
of excess intracellular hexoses to their corresponding
polyols by aldose reductase is the triggering event of
diabetic retinopathy.
8. POTENTIAL THERAPEUTICS:
PREVENTION STUDIES
Evidence that aldose reductase is, indeed, involved
in the retinopathy of these newly available animal
models of diabetes and that drug therapy is feasible
emerged from studies involving treatment of
galactose-fed animals with aldose reductase inhibitors
(Kador, 1990; Kador et al., 1988, 1990; Robison et
al., 1989a,b, 1990c; Robison and Laver, 1993;
Takahashi et aL, 1992).

Table 2. Effect of an Aldose Reductase Inhibitor (M79175) on Incidence* of Dog Retinal Angiopathies,

Cataracts and HGB A IC Levels
Lesion

Pericyte ghosts
Microaneurysms
Mean number per eye
Mean number per eye
Cataract severityt
(6-36 month means)
(5-38 month means)
Hemorrhage
HGB A1C levels:~

Months

Control

36
38
36
38
36
38

0/4
0/4
0/4
0/4

36
38
38

0
0
0/4
0//4
2.20 -1-0.27

Galaetose diet//drug dose
untreated

0.5 m g / k g

5 mg/kg

4/4
4/4
4/4
4/4
15
22

4/4

4/4

4/4

1/2

2.5
2.2
1/4
2//4
2.83 4- 0.37

14

2

2.1

0.7

3/4

0/2

10 m g / k g

16 m g / k g

2/4

1/4

1/4

1/4

1

2

0.3, 2 / 7 clear 0.2, 2 / 6 clear

0/4

0/4

2.56 + 0.07

2.58 5:0.40

* Incidence expressed as the proportion of dogs showing the lesion.
tCataract severity classified by slit-lamp exam on a scale of 0-4, with 4 being the most advanced cataract.
:~Summary of HGB AIC levels determined by HPLC at 3-month intervals for the 4 dogs utilized in each group
expressed as means + standard deviations. Modified from Table 2, Kador et al. (1994) with permission from the authors
and the publisher.
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A set of positive studies on dogs utilized a
homogeneous population of 9-month-old normal
males from an inbred laboratory strain of beagles,
which were age-matched. Eyes were enucleated at
different times, ranging from 19 to 38 months,
permitting observation of diabetic-like retinal
microangiopathies from the earliest signs through the
formation of microaneurysms in untreated galactosefed dogs (Kador, 1990; Kador et al., 1988, 1990,
1994; Takahashi et al., 1992). The treated dogs were
given different doses and combinations of the aldose
reductase inhibitors sorbinil (Pfizer, Groton, Ct.) and
M79175 (Eisai, Tokyo, Japan) administered by oral
tablets both before and after a single daily 30%
galactose meal. The sorbinil doses ranged from 59 to
105 m g / k g / d a y , while the doses of M79175 ranged
from 0.5 to 16 m g / k g / d a y . The body weights
remained equivalent in treated and untreated groups
throughout the experiment. The levels of
galactosemia in all groups of galactose-fed dogs was
also the same throughout, as determined by
measurements of blood galactose and glycated
hemoglobin levels at 3-4 month intervals (Table 2).
Treatment with the higher doses of aldose
reductase inhibitors (M79175 at 5-16 m g / k g / d a y )
completely prevented 'dot and blot' hemorrhages
through 38 months and significantly delayed all other
diabetic-like retinal microangiopathies (Table 2).
Pericyte ghosts normally occurred as early as 19
months and microaneurysms as early as 27 months
following commencement of galactose feeding in
untreated dogs. Their appearance was delayed for
several months in treated dogs, the degree of delay
being directly correlated with drug dose and potency.
A clear ameliorative effect of inhibitor treatment was
demonstrated by detailed analyses of several
parameters (Takahashi et al., 1993). Although the
lower doses delayed rather than prevented the retinal
microangiopathies, the dose-related ameliorative
responses suggest that complete prevention rather
than simply a delay of ocular complications in
galactose-fed dogs is possible if enough aldose
reductase inhibitor is maintained at the cellular level.
The similar glycated hemoglobin (HGB AIC)levels
in untreated and inhibitor-treated dogs (Table 2)
demonstrates that aldose reductase activity, and not
glycation (Section 12.3), caused the diabetic-like
retinopathy. The prevention of 'dot and blot'
hemorrhages and dose-dependent delays of other

retinal micr0angiopathies were directly correlated
with amelioration of sugar cataracts in these same
dogs (Kador, 1990; Kador et al., 1994; Sato et al.,
1991; Takahashi et al., 1992).
Cataracts were completely prevented in one-third
of the dogs treated with doses of 10-16 m g / k g / d a y
(M79175), and their progression was significantly
delayed by lower doses, in a dose-related manner.
The complete prevention of cataracts in some of the
inhibitor-treated dogs was important because the lens
provides a 'built-in control' in diabetic and
galactose-fed animal models: the maintenance of a
clear lens gives the assurance that enough aldose
reductase inhibitor reaches the lens on a regular basis
to block polyol formation (Section 13.5). In the
galactose-fed dogs, there was a direct correlation
between the severity of cataracts and the degree of
retinal damage. Those dogs which had clear lenses
due to aldose reductase inhibitor treatment had
minimal retinal microvascular change. Unless the
conditions are met, in which inhibitor treatment is
capable of ameliorating or completely preventing
cataracts, there is no reason to expect complete
prevention of other ocular complications (Robison
and Laver, 1993, 1994).
Negative findings with respect to the efficacy of
aldose reductase inhibitor treatment of retinal damage
in galactose-fed dogs have also been reported
(Engerman and Kern, 1989, 1991, 1993; Kern, 1991;
Kern and Engerman, 1991). These studies differed
significantly in experimental design and
interpretations from those used by Kador's group, as
indicated in a recent evaluation (Robison, 1994).
Instead of using aldose reductase inhibitors in such a
way as to provide the highest levels of inhibition,
only one, relatively low dose of aldose reductase
inhibitor was employed. Instead of adjusting the
inhibitor administration for ideal pharmacokinetics,
the feeding of galactose was ad libitum and tablets
with aldose reductase inhibitor were administered
once in the morning and once in the evening. By
contrast, in Kador's studies, galactose ingestion was
limited to a single feeding and aldose reductase
inhibitors were administered in three equal doses: 1
hr before feeding, 1 hr after feeding and 8 hr after
feeding. Probably sufficient levels of the aldose
reductase inhibitor were not attained in the target
tissues in the Engerman and Kern studies.
Some of the problems, which make a meaningful
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Fig. 10. Prevention of diabetes-related retinal microangiopathies. Whole mounts of retinal vessels from rats fed a diet with 50%
galactose for 24 months and treated, A, or untreated, B, with an aldose reductase inhibitor, sorbinil (65 mg/kg/day) for the
duration of the experiment. Note that the normal structure of the capillary meshwork (m) was maintained along with a normal
(ca. 1:1.6) ratio of pericyte (p) to endothelial (e) cell nuclei in the sorbinii-treated retina, whereas various microangiopathies
including dilated capillaries (dc), seemingly occluded capillaries (oc), microaneurysms (ma), dilated meshworks (dm) and
various complex microvascular abnormalities, which would be recorded clinically as intraretinal microvascular abnormalities
(IRMA) developed in the untreated galactose-fed rat. X 300. The calibration bars represent 50 ~m. Reproduced from Robison
and Laver (1993) by permission and courtesy of Smith-Gordon and Co. Ltd.
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interpretation of the negative studies difficult
(Robison, 1994), can be summarized as follows: (1)
utilization of a single inhibitor dose; (2) lack of
histological information on retinas until 42 and 60
months following disease onset, when it is too late to
see the delays in microangiopathies documented to
occur" between 20 and 38 months (Akagi and Kador,
1990; Kador, 1990; Kador et al., 1988, 1990, 1994);
(3) failure to prevent retinal capillary basement
thickening (Engerman and Kern, 1991), which is a
well-established effect of adequate doses of aldose
reductase inhibitors (Frank, 1994); (4) interpretation
of polyol measurements on the whole retina given
that the most important concentrations probably occur
in the capillary pericytes, which would be grossly
under-represented in whole retinas; (5) determination
of retinal polyol levels only at termination of the
experiment, when the fewest pericytes would be
present; (6) lack of clear documentation of retinal
microangiopathies by either micrographs or by
quantitative morphometric analyses; and (7) failure
to completely prevent cataracts in either the diabetic
or galactose-fed dogs by the drug dose and/or
administration used. Probably, the experimental
design precluded finding a positive effect of
inhibiting aldose reductase activity.
Findings from inhibitor-treated, galactose-fed rats
were very conclusive. Inhibitor treatment not only
prevented cataracts, but also prevented capillary
basement membrane thickening and the entire
spectrum of diabetic-like microangiopathies through
the mild proliferative stage (Fig. 10). In three studies
totalling 115 rats (23 of which were galactosemic for
> 24 months), galactose-fed rats had high blood
levels of galactose (ca. 200 mg/dl) and polyol (ca.
35 mg/dl) at 6, 18 and 24 months, but were relatively
healthy and had normal life-spans. The retinas of
untreated rats which were galactosemic for 24 months
or more exhibited the full range of diabetic-like
retinal microangiopathies through the mild
proliferative stage (Section 7). All the lesions were
essentially prevented with AL-3152, sorbinil, or
tolrestat, three structurally distinct aldose reductase
inhibitors. The inhibitors were evenly mixed with
fresh diet at 0.1, 0.05 and 0.05% w / w , respectively
(Laver and Robison, 1993; Robison and Laver, 1993;
Robison et al., 1983, 1986, 1988, 1989a,b, 1990c,
1991a). Aldose reductase inhibitor-treated
galactosemic rats had lowered blood polyol levels

( < 3.0 mg/dl), but did not differ significantly from
untreated galactosemic rats in blood glucose,
galactose, or glycohemoglobin levels (Section 13.2).
The treated rats also remained free of cataracts
throughout a period of 28 months, indicating that the
continual oral administration of an aldose reductase
inhibitor was sufficient to prevent tissue damage
(Section 13.5).
These clear findings on the efficacy of aldose
reductase inhibitors in preventing retinopathy in
galactose-fed rats provide strong support for the
positive effects of aldose reductase inhibitors in
galactose-fed dogs and diabetic rats (Kojima et al.,
1985). Together, these independent studies on the rat
and dog models suggest that diabetic retinopathy in
humans may be ameliorated by treatment with a
sufficiently potent aldose reductase inhibitor, if
treatment begins at the time of disease onset.
9. POTENTIAL THERAPEUTICS:
INTERVENTION STUDIES
Since few clinical trials can be purely prevention
studies, interventions in animal models are of
inestimable value for determining how late therapy
can be implemented and still have an effect. Now
that diabetic-like retinopathy can be induced within a
relatively short time in the new, galactose-fed animal
models, intervention studies that were unfeasible
previously can be undertaken.
Thus, a combined prevention and intervention
study was performed using a relatively new aldose
reductase inhibitor (AL-3152) on galactose-fed rats
(Robison et al., 1993) to test the possibilities of: (1)
preventing diabetic-like retinopathy by constant
inhibitor treatment from initiation of 50%-galactose
feeding, and (2) delaying or halting diabetic-like
retinopathy in spite of postponing intervention by
addition of inhibitor or removal of galactose until 6
months after galactosemia was induced. From rats
killed at 6, 18 and 24 months, whole mounts of the
retinal vasculature and transected whole retinas were
used for morphometric analyses with a computerized
image analysis system designed for 1024 × 1024 × 8
bit resolution. The amount of capillary basement
membrane thickening, pericyte loss, capillary
dilation, microaneurysms, acellularity and total length
of capillary were quantitated for each rat. Then the
rats were scored from 0 to 10 based on the numbers
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of lesions in all categories, with the Grade 0
indicating no retinopathy and Grade 10 the maximum
observed.
At 6 months, when intervention was begun, the
untreated galactose-fed rats exhibited a 30%,
statistically significant ( p < 0.01) increase in
capillary basement membrane thickness, pericyte
degeneration and Grade 1 retinopathy overall. By 18
months, the same group had Grade 7 retinopathy
whereas the rats receiving intervention with either
AL-3152-enriched or galactose-free diet exhibited
only Grade 2 retinopathy, and the rats fed control
diet or galactose plus AL-3152 throughout the 18
months demonstrated no retinopathy. At 24 months,
the untreated galactose-fed rats exhibited Grade 10
retinopathy, while those receiving intervention by
galactose removal had a Grade 8.5, and those
receiving intervention with AL-3152 had a Grade 9.
At 6, 18, and 24 months, all the rats that received
galactose for 6 months or more had cataracts, except
those that were treated from the beginning with
AL-3152. All the galactose-fed rats had high levels
of glycated (galactosylated) hemoglobin, whereas
only the untreated galactose-fed rats had high plasma
galactitol levels and developed diabetic-like
retinopathy. In rats receiving intervention by removal
of galactose, the retinopathy had progressed even
though glycated hemoglobin and plasma polyol levels
had been normalized. Because only rats which had
high polyol levels for at least 6 months also exhibited
retinopathy, it would appear that this diabetic-like
complication is probably initiated by polyol
accumulation and not by excessive tissue glycation,
although increased glycation occurs with galactose
feeding. The levels of glycohemoglobin did not
correlate with either cataracts or retinopathy. In
conclusion, cataracts and diabetic-like retinopathy
are both prevented in galactose-fed rats if treatment
with AL-3152 is started simultaneously with the
galactose insult. But, intervention after 6 months by
removal of galactose or addition of AL-3152 provides
only a delay albeit a significant one.
The findings in galactose-fed rats are consistent
with intervention studies in diabetic animals
(Engerman and Kern, 1987; McCaleb et al., 1991),
which also indicate that reversal does not occur and
halting of damage is limited. The effect of
intervention therapy was studied in diabetic dogs
receiving poor glycemic control for 2.5 yr followed
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by good glycemic control for another 2.5 yr
(Engerman and Kern, 1987). No microaneurysms
developed in the 2.5 yr of poor glycemic control.
However, in spite of intervention with good glycemic
control for the next 2.5 yr, many microaneurysms
formed and the overall vessel damage was greater
than that found in diabetic dogs receiving good
glycemic control for 5 yr. Intervention in humans by
laser photocoagulation (Alello, 1994; ETDRS,
1991d,f) or pituitary ablation (Speakman et al., 1966)
decreases hemorrhages and proliferative changes, but
does not reverse all the lesions of diabetic
retinopathy. Pancreas transplantation in humans must
be relatively early in order to demonstrate a clear
effect (Petersen et al., 1990).
The cumulative evidence indicates that probably
only a delay or halting of ongoing degenerations is
all that can be effected once diabetes-related retinal
vessel damage has progressed significantly. Perhaps
there is a damage threshold beyond which reversal is
impossible, as in sugar cataracts (Hu et al., 1983;
Simard-Duquesne and Dvornik, 1973). Once an
intramural pericyte has degenerated, it would be
replaced very slowly if at all (Engerman et al.,
1967). So, while prevention therapy could completely
prevent loss of pericytes, intervention therapy would
only be expected to prevent any further loss of
pericytes. Assuming that pericyte loss initiates
subsequent vessel lesions (Section 12.4), halting of
pericyte loss by intervention would not halt
subsequent lesions in those capillaries that had
already lost several pericytes. The disease progression
would be expected to continue until the effects of
lost pericytes were exhausted. Evidence of beneficial
effects of intervention therapy may be masked for a
long time, until such existing tissue damage
completely reveals its consequences.
I0. CLINICAL TRIALS

Insofar as plasma glucose can be maintained at
normal levels, the complications of diabetes should
be preventable. Insulin is a miracle drug for an
increasing number of people whose lives depend on
artificially maintaining blood glucose levels in a near
normal range. Insulin treatment, when designed to
provide the tightest possible blood glucose control
by multiple injections or continuous subcutaneous
insulin infusion pumps (DCCT, 1993; Reichard et
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al., 1993; Santiago, 1992), has significantly delayed

the progression of diabetic complications, including
diabetic retinopathy. This is what would be expected
if hyperglycemia and/or the metabolic products of
glucose are the initiating factors. However, tight
glucose control methods are not able to bring the
blood glucose below supernormal levels nor
completely normalize glycosylated hemoglobin levels
in all patients (DCCT, 1993; Reichard et al., 1993;
Santiago, 1992; Zinman, 1989). Tight control brings
problems of its own, such as higher risks of increased
body weight, hypoglycemic shock and ketoacidosis
(DCCT, 1993; Reichard et al., 1993; Santiago, 1992).
The methods used to obtain tight glucose control
would be difficult to implement in the general
population of diabetic patients without significant
risks. A new approach to preventing diabetic
complications is needed.
Aldose reductase inhibitors used in addition to
conventional insulin treatment have the potential of
blocking the toxic effects of the supernormal levels
of glucose, which the best insulin therapy is unable
to avert. A 3-yr, multi-center clinical trial to test the
aldose reductase inhibitor sorbinil as a
complementary treatment of diabetic retinopathy
demonstrated no clear beneficial effect, although it
did indicate "...a slightly slower progression rate in
the microaneurysm count among patients assigned to
take sorbinil..." (Sorbinil Retinopathy Trial Research
Group, 1990, p. 1234). Why were negative results
found in the clinic when the animal data (Sections 8
and 9) predicts potential beneficial effects? There are
at least three possible explanations: (1) less than
adequate drug dosing; (2) intervention too late
with respect to disease progression; and/or (3) study
too short to distinguish between the full expression
of existing damage and beneficial effects of therapy.
Drug levels probably played a very important
role, as suggested by animal studies, which
demonstrated a direct correlation between drug dose
and the ameliorative effects of aldose reductase
inhibitors (Section 8). Intervention time and length
of the study were undoubtedly very important also.
Prevention studies can 'be designed to be
straightforward in animals (Section 8). However,
most clinical trials are intervention studies by nature
and, as such, are plagued with many unknown
variables related to the degree of tissue damage
present at the time of intervention (Section 9).

Intervention with good glycemic control in diabetic
dogs led to the conclusion that "...retinopathy may
be preventable but tends to resist arrest even in its
incipient stages, before more than the first few
aneurysms have appeared..." (Engerman and Kern,
1987, p. 808). The acceptance criteria for the sorbinil
trial included patients with as many as five
clinically-visible (patent) microaneurysms and an
unknown number of occluded microaneurysms and
microscopic lesions such as pericyte loss, capillary
basement membrane thickening and endothelial cell
proliferation. Concerns regarding the amount of such
existing damage at the time of first clinical detection
of diabetic retinopathy were expressed years ago,
when retinal flat mounts first permitted
histopathological correlations: "...it has not
previously been realized how surprisingly numerous
micro-aneurysms are and the picture is a depressing
one for one wonders how it can ever be possible to
reverse such a gross and widespread process by the
administration of drugs or the control of diet. At best
we can only hope to prevent the development of
such lesions or, once the condition is established, to
attempt to control the hemorrhages..." (Ashton, 1950,
p. 41). The sorbinil study was relatively short
compared to the time required for diabetic retinopathy
to develop. It is possible that a beneficial effect of
sorbinil would have been distinguishable from the
progression of existing damage had the study lasted
longer than 3 or 4 yr. This appears to be the most
plausible explanation why relatively short-term
studies on the efficacy of tight blood glucose control
(Kroc Collaborative Study Group, 1984) failed to
demonstrate an ameliorating effect on diabetic
retinopathy. Recent long-term trials (DCCT, 1993;
Reichard et al., 1993; Santiago, 1992) demonstrated
a clear benefit, which would have been missed if the
studies had been terminated earlier.
Findings from recently completed clinical trials
and studies on animal models of diabetic retinopathy
suggest that future clinical trials would benefit by
including some of the following: (1) earliest possible
intervention; (2) more potent a n d / o r higher doses
of inhibitors; (3) inhibitors with better
pharmacokinetics; (4) longer trials; and (5) means
for earlier diagnosis. A current multicenter trial to
test the efficacy of tolrestat (Macleod et al., 1992)
has incorporated many of these features.
Tolrestat has pharmacokinetics (Dvornik et al.,
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1988, 1994) consistent with a once-a-day dosing in
humans (plasma half-life of 12 hr), has been
demonstrated to be efficacious in preventing
diabetic-like retinopathy in rats (Robison et al.,
1989a, 1990c), is well-tolerated in humans (Sima et
al., 1993; Santiago et al., 1993), and has been
demonstrated to interrupt the diabetes-induced
progressive loss of nerve function in a double-blind,
placebo-controlled clinical trial involving 372
patients with a long history of diabetic neuropathy
(Santiago et al., 1993). This effect on nerve function
was associated with reduction in structural signs of
axonal degeneration, decreased incidence of myelin
abnormalities and increased evidence of fiber
regeneration. Currently tolrestat is being evaluated in
long-term clinical studies in patients with diabetic
nephropathy and retinopathy.

11. SUBORDINATE HYPOTHESES:
COMPONENTS OF THE
PATHOPHYSIOLOGICAL SPECTRUM
Although there is a spectrum of retinal
microangiopathies unique to diabetic retinopathy
(Section 5), various facets of the spectrum are
exhibited in other disorders and may develop from
secondary factors held in common. A single
hypothesis probably defines the initial lesion (Section
12.4), but several subordinate hypotheses may be
needed to explain the individual secondary changes
in the triggered chain of events leading to the final
complexity of vessel damage in diabetic retinopathy.
Probably, the more advanced the lesion, the greater
the possibility of it having a multi-factorial origin.
As expressed by Bloodworth (1964, p. 81), "Diabetic
retinopathy is a combination of degenerative,
proliferative, and exudative lesions of vascular and
parenchymal tissues." Indeed, many hypotheses have
been proposed and variously modified over the years
to explain the component retinal angiopathies
individually or as groups. It has been proposed that
microaneurysm formation may involve more than
one mechanism acting in concert, with pericyte
dysfunction being the primary aberration
(Fryczkowski et al., 1991). Biochemical studies on
the mechanisms of diabetic retinopathy have been
classified into two categories (Frank, 1994) as
follows: (1) those determining the earliest lesions
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(triggering events) and (2) those that might contribute
to retinal-vitreal neovascularization. A discussion of
all the hypotheses proposed to date is beyond the
scope of this review, so only a select number will be
covered with emphasis on the ones that might explain
some of the major component angiopathies (Sections
11.1-11.5) or define the primary event (Section 12).
Neovascularization will not be discussed since it is a
late event and is the subject of many recent reviews
(Bobik and Campbell, 1993; Casey et al., 1994;
Davis, 1994; D'Amore, 1994; Forrester et al., 1993;
Glaser, 1994a; Grant et al., 1993; Klagsbrun and
D'Amore, 1991; Sunderk~itter et al., 1994). The sum
of the evidence in this section suggests that, while
various vessel occlusive factors and perfusion
pressure contribute to the spectrum of lesions
characteristic of diabetic retinopathy, they probably
do not represent the initiating event or provide an
explanation for all the changes that develop, Capillary
lesions are involved in the greatest number of
angiopathies, suggesting that they are closer to a
primary event than arteriolar and venular aberrations
(Fig. 1).

11.1. Rheological
Occlusions

Anomalies

Related

to

Many characteristics of retinal blood flow become
altered in diabetes and have been considered to be
candidates for underlying factors in the development
of diabetic retinopathy (Feke et al., 1994; Frank,
1994). Hatchell and Sinclair (1994) proposed that
abnormal leukocyte rheology could be a prime cause
of diabetic retinal microangiopathies. They suggested
that leukocyte activation alone could initiate enough
endothelial cell damage to induce capillary occlusion,
whereas platelet aggregation, increased whole blood
viscosity or decreased erythrocyte deformability
would not produce sufficient change. They
hypothesized that leukocyte activation may gel the
cytoplasm and result in decreased cell deformability
and increased leukocyte adherence to endothelial
cells.
Naturally occurring human disorders provide
insight regarding certain diabetes-related
angiopathies. One example, which relates to a
potential role of increased blood viscosity and flow
resistance in angiopathies, is the sickling cell
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condition. This disease involves an inherited change
of erythrocyte shape and flow characteristics (Cohen
and van Houten, 1994; Goldberg, 1976; Lutty et al.,
1994; Stefansson et al., 1983). The sickle cell
retinopathy that develops (Garner, 1994) includes
hemorrhages, vessel tortuosity, arteriolar occlusions,
arteriolar-venular anastomoses, areas of nonperfusion, cotton-wool spots and proliferative
retinopathy. Compared to diabetic retinopathy, the
hemorrhages tend to be much larger, the arteriolar
occlusions are mainly equatorial and peripheral, the
cotton-wool spots are extremely rare, and the
neovascularization is mainly in the peripheral retina.
Notably absent are microaneurysms and hard
exudates.

11.2. Capillary Occlusion and Ischemia

Capillary occlusion has been suspected as a
primary cause of diabetic retinal lesions. Radiation
retinopathy induced in monkeys (Irvine and Wood,
1987) could be considered a test for the potential
role of capillary occlusion and ischemia. As in
diabetic retinopathy, the first changes occur in the
small capillaries of the deep plexus. As in human
radiation retinopathy (Archer et al., 1991; Chaudhuri
et al., 1981; Hayreh, 1970; Maguire and Schachat,
1994) and diabetic retinopathy, there is a delay
('silent' period) before any effects of the insult
can be detected. After approximately 12 months,
there is a focal loss of endothelial cells and
then pericytes" from the capillary walls. These are
followed by capillary occlusions and subsequent
occlusions of larger vessels with accompanying
non-perfusion and cotton-wool spots. Finally,
microaneurysms, increased permeability, intraretinal
neovascularization and rubeosis iridis develop. The
lesions are similar to those of diabetic retinopathy
except that there are fewer microaneurysms, no
intravitreal neovascularization, and the first lesion is
the selective loss of endothelial cells rather than
pericytes.
Retinal ischemia was induced experimentally in
cats by raising the intra-ocular pressure, by
photocoagulation of individual arteries or by
embolization of capillaries with sterile fat emulsions
(Reinecke et al., 1962). The retinal capillaries
responded similarly to all three methods. Ischemia

lasting less than 90 min resulted in endothelial cell
proliferation in the capillaries,-while ischemia for
longer periods caused an initial increase in endothelial
cell number, then a loss of endothelial cells, and
finally pericyte degeneration, leaving acellular
capillaries. Laser-induced occlusion of retinal
arterioles in rats resulted in increased numbers of
neutrophils in retinal capillaries (Hatchell et al.,
1994b). This suggests involvement of neutrophils in
capilary plugging and a possible contribution to the
non-perfusion observed following acute retinal
ischemia.
11.3. Arterial and Arteriolar Occlusions

Michaelson (1980) suggested that arteriosclerosis
is a prominent feature of diabetic retinopathy. Ashton
(1953, 1963) presented histological evidence for
narrowing of arterioles in eyes with diabetic
retinopathy and suggested that ischemia is the basic
problem of diabetic retinopathy. Focal occlusions of
small arterioles are common in diabetic retinopathy
and occur mainly in the posterior pole where other
diabetic angiopathies develop. The microinfarctions
result in the clinical appearance of cotton-wool spots
(Destro and Gragoudas, 1994) which may occur very
early in diabetic retinopathy (Kohner et al., 1969).
The retinal effects of arterial occlusion are
demonstrated by naturally occurring disorders such
as ocular ischemic syndrome and retinal obstructive
disease. The characteristics of these disorders are
dilated veins, hemorrhages (often in macula),
microaneurysms in the midperiphery, cotton-wool
spots, vessel leakage, and neovascularization on the
disc and elsewhere (Brown, 1994a,b). Notably absent
are numerous microaneurysms in the posterior pole,
tortuous vessels and IRMA, when compared to
diabetic retinopathy. Cogan (1974) reported that a
diabetic patient developed typical non-proliferative
retinopathy in one eye, but had no funduscopicaUy
visible diabetic microangiopathies in the contralateral
eye, which previously had an occlusion of the central
retinal artery.
Experimental occlusion of retinal arteries in cats
induced the formation of many arterio-arteriolar and
veno-venous shunts as well as capillary acellularity
(Henkind, 1966). However, no arterio-venous shunts
or microaneurysms developed, both of which are
very characteristic of diabetic retinopathy.
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11.4. Venous and Venular Occlusions

Many, but not all, aspects of diabetic retinopathy
are mimicked by venous occlusion. Experimental
venous occlusion was produced in a non-diabetic
monkey eye by a laser burn accurately applied to
avoid retinal artery damage (Hamilton et al., 1974).
The resulting closure of the retinal vein induced
essentially all the lesions that occur in human retinal
venous occlusion (Cogan, 1974; Weinberg and
Seddon, 1994), but did not exhibit all the angiopathies
of diabetic retinopathy. There were intraretinal
hemorrhages (but mainly small and flame-shaped),
capillary dilations, preferential (enlarged and
tortuous) channels within the capillary bed, tortuous
venules, areas of capillary non-perfusion, secondary
arteriolar and venule occlusions and eventual
revascularizations (Hamilton et al., 1974). Notably
missing were microaneurysms, pre-retinal
neovascularization and cotton-wool spots. Other
experimental models of venous occlusion (Wallow et
al., 1991) have developed capillary and venous
collaterals within the retina, similar to those
characteristic of diabetes. However, no
microaneurysms developed and the intramural
pericytes remained unchanged or increased in their
coverage of the capillary surface (Wallow et al.,
1991).
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having many exudates not confined to the posterior
pole, having fewer microaneurysms mainly
associated with the arterial side of the retinal
circulation, having mainly flame-shaped rather than
punctate hemorrhages, and having basement
membrane thickening of arterioles, but not capillaries.
In addition, there is no selective loss of pericytes.
Collateral channels induced by experimental
occlusion of retinal arteries developed no
microaneurysms in spite of carrying blood under
pressure probably in excess of that normally present
in the capillary plexus (Henkind, 1966).
12. MAJOR HYPOTHESES: UNDERLYING
MECHANISMS OF DIABETIC
RETINOPATHY

The major hypotheses proposed to explain the
underlying mechanism and possible triggering lesion
of diabetic retinopathy are the following, in
approximate order of greatest supporting evidence:
(1) increased aldase refluctase activity (Frank,
1991a, 1994; King and Banskota, 1994); (2) nonenzymatic glycation (Frank, 1991a, 1994; King and
Banskota, 1994) (3) altered redox potential (King
and Banskota, 1994); and (4) the diacylglycerolprotein kinase C pathway (King and Banskota,
1994).

11.5. Vessel Dilation and Vascular Perfusion
Pressure

12.1. Key Involvement of Hyperglycemia

It has been proposed that retinal vessel dilation
and wall stretching caused by increased retinal blood
flow, increased perfusion pressure and/or vessel
occlusion could cause many diabetic retinal
microangiopathies involving endothelial cell
proliferation and neovascularization (Stefansson et
al., 1983). It was suggested that added luminal
pressure could cause the endothelial cells of venules
and capillaries to stretch, leak at junctions, and
proliferate, producing microaneurysms, capillary
dilation, and neovascularization. Hypertension
retinopathy can. serve as a test of hypotheses
involving increased tension (Anand and Tasman,
1994; Brown and Benson, 1984; Garner, 1994). It
results in retinal hemorrhages, cotton-wool spots,
marked papilledema, hard exudates and capillary
non-perfusion. It differs from diabetic retinopathy in

Certainly hyperglycemia (or excess in any blood
hexose) must play the principal role in the
development of diabetic retinopathy and must be
central to any hypothesis proposed. The importance
of hyperglycemia has been recognized by several
investigators (Ashton, 1959; Davis, 1988; Frank,
1994; Garner, 1994). Strong supporting evidence
includes the following: (1) relation of glucose control
to retinopathy in diabetic dogs (Engerman and Kern,
1987; Engerman et al., 1977); (2) a similar
relationship in epidemiological studies (Klein et al.,
1988); (3) demonstration that diabetic retinopathy is
directly related to blood glucose levels (DCCT,
1993); (4) the fact that Type I and Type II diabetes
are very different in many ways, including origin,
development, carbohydrate metabolism, fat
metabolism and insulin levels (Fong and Rand, 1994),

624

W. G. Robison et al.

yet they share similar retinopathies and chronic
hyperglycemia (Cogan, 1974); and (5) the fact that
diabetic-like retinopathy can be induced in normal
animals by a galactose diet (Sections 6.5 and 7). The
galactose-fed animal permits isolation of the effects
of high blood hexose from all other complicating
factors of the systemic disease. This permits a clear
distinction between systemic diabetes and the
complication (diabetic retinopathy). In galactose-fed
animals, the plasma levels of insulin and glucose
remain normal, yet diabetic-like retinopathy develops
(Sections 6.5 and 7). The retinopathy must result
solely from high hexose (galactose) or the products
of its metabolism.

indicates that inhibition of sorbitol dehydrogenase in
diabetic animals accelerates cataract formation, a
finding expected with polyol involvement, but not
expected if altered NADH/NAD ratio were the
primary event. In order for altered redox potential or
increased flux through the diacylglycerol-protein
kinase C pathway to be considered primary causative
factors, independent of aldose reductase activity, the
source of increased NADH/NAD ratio would have
to be demonstrated to occur prior to aldose reductase
action and the glucose-induced increase in redox
potential should not be prevented by aldose reductase
inhibitors.
12.3. Glycation (Non-enzymatic Giycosylation)

12.2. Altered
Redox
Potential
and
Diacylglycerol-Protein Kinase C Pathway

Both of these hypotheses are secondary to the
increased activity of aldose reductase that is induced
by hyperglycemia. The additional flux through the
polyol pathway that occurs in diabetes increases the
intracellular ratio of NADH/NAD (King and
Banskota, 1994; Williamson et al., 1993), creating a
condition called pseudohypoxia (Williamson et al.,
1993) because the NADH/NAD ratio is also altered
when oxygen deficits prevent oxidation of NADH to
NAD +. Not only would the redox potential be
increased, but there could be an increased flux
through the diacylglycerol-protein kinase C pathway,
explaining the increased protein kinase C activity
observed in diabetic tissues (King and Banskota,
1994). However, consideration of these hypotheses
as primary would fail to explain evidence from
galactose-fed animals. The proposed alteration of the
redox potential requires not only increased reduction
of excess hexose to polyol by aldose reductase, but
also the oxidation of the polyol (sorbitol to fructose
in diabetes) by sorbitol dehydrogenase. Since, unlike
sorbitol, galactitol is not metabolized by the cell, no
NADH is produced by the polyol pathway in
galactose-fed animals, yet they develop a retinopathy
indistinguishable from diabetic retinopathy (Section
7). Glycolysis, another potential source of an
increased ratio of NADH/NAD, has not been
demonstrated to occur in galactose-fed animal
models, although preliminary data has been
mentioned (King and Banskota, 1994). Recent
evidence (Geisen et al., 1994; Lee et aL, 1995)

Glycation is an important direct cumulative effect
of hyperglycemia. It involves the non-enzymatic
covalent bonding between free aldehyde groups on
any of several sugars and amino groups of proteins,
usually lysines (glucose - - glycosylation; galactose
- - galactosylation; fructose - - fructosylation; and so
on). The initial products of glycation are unstable
Schiff bases that become stabilized by undergoing a
reduction. Then they develop susceptibility to
oxidation, undergoing repeated glycation-oxidation
cycles and becoming highly crosslinked in
irreversible reactions involving other compounds
(Amadori rearrangements). Both intermediate and
advanced end-products of glycosylation (AGE), such
as ketoamides (early products of the Maillard, or
browning reaction) resist turnover and accumulate in
multiply-crosslinked moieties. The accumulation of
glycoxidation products precedes continually, as a
facet of the normal aging process, and is significantly
accelerated in diabetic subjects (Baynes, 1991; Bunn
et al., 1978; Sternberg et al., 1985). In non-diabetic
individuals, the glycoxidation products accumulate
mainly in extracellular matrix components such as
tissue collagens. However, under diabetic conditions,
significant accumulations also occur intracellularly,
in cells that do not require insulin for glucose uptake
(Chiou et al., 1980; Nagaraj and Monnier, 1992;
Nagaraj et al., 1991). Since glycation is a chronic,
non-enzymatic process directly related to glucose
levels, which causes marked accumulations of
irreversible reaction products (advanced glycation
end-products), it has been attractive to propose its
involvement in diabetic complications (Brownlee,
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1990; Brownlee et al., 1988; Perry et al., 1987).
However, hard evidence for a cause-effect
relationship between glycated end-products and
diabetic retinopathy is not yet available.
The main report which claims to have
demonstrated prevention of retinal microangiopathies
by inhibiting the formation of advanced glycation
end-products (Hammes et al., 1991) is not
accompanied by adequate supporting data. Although
37.5% (three out of eight) of the untreated diabetic
rats and none of the aminoguanidine-treated rats
were reported to have microaneurysms, the
micrograph presented (their Fig. 2c) as raw data does
not demonstrate a microaneurysm, but a twisted
capillary, or perhaps a capillary loop (Garner, 1970)
combined with an adjacent twist. Therefore, the
numerical data presented are of questionable value
and do not provide the support needed to identify
glycation as an initiating cause of diabetic
retinopathy. The increase in glycation end-products
reported in the capillary basement membranes of
diabetic rats is expected based on human studies
(Sternberg et al., 1985), but there is no unequivocal
evidence that the increased glycation contributes to
the thickening of basement membranes in humans or
animals. A thickened basement membrane would be
expected to become more heavily glycated solely on
the basis of the additional material available for
glycation. The only agents known to unequivocally
prevent diabetes-related basement membrane
thickening are inhibitors of aldose reductase (Das et
al., 1990; Frank et al., 1983; Robison and Nagata,
1988; Robison et al., 1983, 1986, 1988), which have
no significant effects on plasma glucose levels in
diabetic rats (Kemper and Dvornik, 1986; Yue et al.,
1984) or on blood hexose and glycohemoglobin levels
in galactosemic rats (Robison et al., 1989a, 1993;
Yue et al., 1984; Section 13.2).
Aspirin has been reported to inhibit glycation and
delay cataract formation in streptozotocin diabetic
rats (Cherian and Abraham, 1993; Swamy and
Abraham, 1989), but it is not efficacious in
preventing diabetic cataracts or delaying the
progression of retinopathy in diabetic patients,
according to recent clinical trials (Seddon et al.,
1991; ETDRS, 1991b). Perhaps glycation should be
considered to be a possible factor in rendering some
of the diabetes-induced alterations in vascular
structure irreversible. However, long-term studies on
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animal models of diabetes are needed to determine
the efficacy of various guanidines, including
aminoguanidine, and/or other agents that inhibit
formation of glycoxidation products (Fu et al., 1994)
or block the recently proposed link with nitric oxide
formation (Tilton et al., 1993).
Meanwhile, the bulk of the evidence is consistent
with a primary role for aldose reductase activity in
ocular complications of diabetes (Section 12.4), but
would not be expected if glycation were the initiating
event: (1) although blood glucose levels can be very
high (ca. 500 mg/dl) in the diabetic rat, the blood
galactose levels remain relatively low (ca. 200
mg/dl) in the galactose-fed rat (Robison et al.,
1989a), yet sugar-induced cataracts and retinopathy
take much longer to develop in the diabetic than in
the galactose-fed rat (Datiles et al., 1982; Robison
et al., 1989a, 1990c, 1991b); (2) congenitally
hyperglycemic mice with high glycation levels do
not develop cataracts, even when fed galactose,
apparently because their lenses exhibit only one-tenth
of the aldose reductase activity found in rat lenses
(Varma and Kinoshita, 1974); (3) the degu rodent,
which is essentially normo-glycemic (150 mg/dl
blood glucose) but has high lens aldose reductase
activity, develops a cataract after ingesting normal
laboratory rat chow and develops a cataract much
sooner than any other rodent (within 10-12 days) if
made diabetic (465 mg/dl blood glucose) by
streptozotocin injection (Varma et al., 1977); (4)
glycated hemoglobin levels remain unchanged in
galactose-fed dogs and rats treated with aldose
reductase inhibitors (Kador, 1990; Kador et al., 1990,
1994; Engerman and Kern, 1991; Kern and
Engerman, 1991, 1995; Robison and Laver, 1993;
Robison et al., 1993; Section 13.2), yet cataract
development and retinal vascular abnormalities are
ameliorated (Kador et al., 1994; Robison and Laver,
1993, 1994); (5) inhibition of aldose reductase
prevents the galactose-induced cataracts in rats
without decreasing the elevated glycosylation levels
of the lens proteins (Chiou et al., 1980); (6)
inhibition of aldose reductase prevents hexoseinduced retinal capillary basement thickening (Frank
et al., 1983; Robison et al., 1983, 1986) and
advanced retinal microangiopathies in rats without
altering the blood insulin, glucose, galactose
(Robison et al., 1989a, 1990c; Robison and Laver,
1993) or glycohemoglobin levels (Robison et al.,
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1993; Section 13.2); (7) although pentosidine starts
accumulating soon after galactose feeding (Nagaraj
et al., 1994), it remains to be demonstrated that
advanced glycation end-products could accumulate
fast enough to cause the rapid development of some
complications of hyperglycemia such as the sugar
cataracts (Section 12.4), which correlate closely with
the incidence of diabetic retinopathy (Sections 8 and
13.5); and (8) transgenic mice that express aldose
reductase activity in the lens develop cataracts at
rates directly correlated with the amounts of polyol
that accumulate in diabetes and galactosemia (Lee et
al., 1995), leaving little doubt that increased aldose
reductase activity causes sugar cataracts.
12.4. Aldose Reductase Activity
Rapid accumulation of intracellular polyol,
resulting from increased aldose reductase activity, is
one of the first and most dramatic tissue responses to
hyperglycemia in cells that do not require insulin for
glucose uptake (Dvornik, 1987; Dvornik et al., 1988,
1994; Kinoshita and Nishimura, 1988; Simfin et aL,
1993). Polyol accumulation is accompanied by tissue
damage. In sugar cataracts, the lens epithelium, which
is the cell layer with the highest concentration of
aldose reductase in the lens, incurs the earliest
ultrastructural damage, correlated directly with the
rapid accumulation of polyol (Robison et al.,
1990a,b).
In a series of experiments (Robison et al.,
1990a,b), Sprague-Dawley rats were made diabetic
by streptozotocin injection (50 m g / k g body weight
in tail vein) or galactosemic by feeding a 30 or 50%
galactose diet and were treated with one of two
aldose reductase inhibitors (AL-1576: 4.0
m g / k g / d a y or sorbinil: 65 mg/kg/day). Plasma
sugar levels were monitored and rats were killed at
several intervals during the first 6-120 hr after
injection or diet administration, and at a few intervals
up to 3 months later. Polyol levels were measured in
epithelium dissected free of contaminating fibers.
Three to four individual epithelial layers were pooled
from different rats for each of the three to six
samples analyzed in each group. The intracellular
levels of sorbitol and galactitol were made using a
modified liquid chromatography procedure, which
permits detection in the picomole range (Dickerson
and Lou, 1990). Whereas mature sugar cataracts took

from 3 weeks to 3 months to develop in 50%
galactosemic and diabetic rats, respectively, the
epithelial cells demonstrated rapid changes in both
polyol levels and ultrastructure. The lens epithelial
cells of streptozotocin-induced diabetic rats exhibited
a 24-fold increase in polyol (sorbitol) accumulation
within 48 hr after streptozotocin injection compared
to controls (Fig. 2A). The lens epithelium of rats fed
30% galactose after a 24-hr fast exhibited a 17-fold
increase in polyol (galactitol) accumulation within
only 36 hr of commencing the diet (Fig. 2B). Analysis
by light and electron microscopy revealed that the
first detectable histopathologies of the lens (as early
as 36 hr in the 50% galactose-fed rats) occurred in
the anterior, central lens epithelial cells. The salient
lesions were cell edema, apparent dilution of
cytoplasm, rounding of nuclei, aberrant intracellular
vacuoles and loss of normal tortuosity of cell
boundaries. No changes were detectable in the
controls or in any of the rats treated with an aldose
reductase inhibitor. The findings indicate a major
role for aldose reductase in hyperglycemic damage
to the lens epithelium. This layer is the principal site
of the important regulator mechanisms that are lost
early in sugar cataractogenesis.
In retinal capillaries, the highest level of aldose
reductase activity is in the intramural pericyte. Aldose
reductase, its mRNA and its product (polyol) have
been localized in pericytes, where one of the first
histopathological lesions of diabetic retinopathy
occurs. Immunohistochemical staining of aldose
reductase in pericytes was demonstrated in trypsindigested capillary whole mounts of dogs (Akagi et
al., 1986) and humans (Akagl et al., 1983).
Messenger RNA encoding for aldose reductase was
identified in cultured human retinal pericytes by
Northern blot hybridization (Nishimura et al.,
1988b). Aldose reductase activity was demonstrated
in isolated dog retinal capillaries (Kern and
Engerman, 1985), cultured monkey (Buzney et al.,
1977) and human (Hohman et al., 1989) retinal
pericytes. The pericytes demonstrated rapid
accumulation of polyols, vacuole formation and
decreased proliferation when incubated in relatively
high concentrations ( > 30 mM) of hexose sugars, but
demonstrated control levels of polyols and no damage
when an aldose reductase inhibitor was included.
The recent in vitro demonstration of a 5.5-fold
greater glucose transport activity in pericytes
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compared to endothelial cells and a selective downregulation of glucose transport activity in pericytes
(Mandarino et al., 1994) suggests a possible relation
to the increased aldose reductase activity in pericytes
and their selective loss in diabetes. Since aldose
reductase is concentrated in a cell that is so
strategically located in the capillary and is the first to
degenerate, it is highly likely that polyol formation
by aldose reductase activity is the primary triggering
lesion of diabetic retinopathy.
The mechanistic link between the toxic effects of
aldose reductase activity in the pericyte and the
histopathologies that develop subsequently is not
completely understood. However, current evidence
reveals close relationships between aldose reductase,
early thickening of capillary basement membranes,
early dysfunction and/or loss of intramural pericytes,
endothelial cell proliferation and the formation of
many proliferation-related vessel lesions. Basement
membrane thickening is directly related to the polyol
pathway and not to glycation. A diabetic-like
basement membrane thickening was demonstrated in
retinal capillaries of rats fed 50% galactose for 7
months (Robison et al., 1983, 1988), 11 months
(Robison et al., 1983), 22 months (Robison et al.,
1986) or 24 months (Robison et al., 1993) and in
rats fed 30% galactose for 21 months (Frank et al.,
1983). The thickening was prevented with three
structurally-distinct aldose reductase inhibitors in two
independent laboratories. Although data on glycated
hemoglobin was not included in those studies, it has
been demonstrated subsequently (Robison et al.,
1993; Section 13.2) that glycation levels are not
altered by treatment of galactose-fed rats with aldose
reductase inhibitors, consistent with earlier findings
on lens proteins (Chiou et al., 1980). Not only
retinal capillary basement membrane thickening, but
loss of pericyte-endothelial cell contacts, and the
proliferation of retinal capillary endothelial cells were'
prevented with aldose reductase inhibitors in
galactose-fed rats (Robison and Laver, 1993; Robison
et al., 1989b).
There is an intriguing relationship between
capillary basement membrane thickening and
pericyte-endothelial cell interaction. A 2.4-fold
increase in retinal capillary basement membrane
thickening is accompanied by a 70% decrease in the
number of cell-to-cell contact regions between
pericytes and endothelial cells in rats fed 50%
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galactose for 28 months (Robison et al., 1989b).
Since each of the contact regions contains several
different types of cell membrane junctional
complexes, the loss of a cell contact fenestra could
mean loss of various functions. Upon finding that
pericyte degeneration, the primary lesion of human
diabetic retinopathy, was "...accompanied by
proliferation of vessels within the retina and into the
vitreous...", Kuwabara and Cogan (1963, p. 498)
proposed that pericytes normally control endothelial
cell proliferation and thus prevent neovascularization.
Crocker et al. (1970) observed that the endothelial
cell proliferation, which results in new capillary
growth during normal wound healing, ceased as the
new vessels became ensheathed by pericytes and as
cell contacts were formed. They hypothesized that a
form of contact inhibition like that reported in cell
culture might explain the decrease in cell proliferation
with increasing numbers of cell contacts. Bovine
retinal pericytes co-cultured with endothelial cells
(Orlidge and D'Amore, 1987) inhibited their
proliferation through the action of transforming
growth factor [3 (TGF-I3). The loss of pericyteendothelial cell contacts plus dysfunction of such a
growth-factor-mediated mechanism may be involved
in the endothelial cell proliferation that is
characteristic of diabetic retinopathy (Cogan et al.,
1961; Kohner and Henkind, 1970). It has been
suggested that pericytes and their products might be
involved in normal blood flow, capillary permeability
and phagocytosis (Miller and Sims, 1986; Sims,
1991; Sims et al., 1990), all of which would be lost
with pericyte degeneration. Consideration of all the
evidence suggests there is a link between pericyte
aldose reductase activity and endothelial cell
proliferation, a major contributor to subsequent
intraretinal anomalies such as microaneurysms and
IRMA.

13. SIGNIFICANCE OF THE

GALACTOSE-FED RAT
The galactose-fed rat provides the best evidence
to date that aldose reductase activity is firmly linked
to all the retinal lesions of diabetic retinopathy. The
findings indicate that the reduction of excess hexose
by aldose reductase is not only the triggering event,
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but that it causes a cascade of cellular and tissue
responses that ultimately result in all the
microangiopathies of diabetic retinopathy through
the mild proliferative stage. This model permits the
dissociation of the effects of polyol accumulation
from those of elevated blood glucose, elevated
glycation levels, decreased insulin production and/or
recognition, as well as other metabolic and genetic
factors which might be involved in the development
of diabetic complications. Only polyol-related
complications and associated aspects s}l~uld be
manifest in a galactose-fed rat. Because of'its greater
accumulation of polyol, the galactose-fed rat model
also permits accelerated development of polyolrelated diabetic complications, a real advantage in
studies of complications that take a long time to
develop i.e. retinopathy.
The fact that the galactose-fed rat closely mimics
human diabetic retinopathy through the mild
proliferative stage (Robison et al., 1983, 1986,
1989a, 1990c; Robison and Laver, 1993; Laver and
Robison, 1993) strongly suggests that the activity of
aldose reductase is the primary causative factor.
However, galactose feeding not only increases tissue
polyol accumulation, but also glycation levels.
Prevention of the retinopathy with aldose reductase
inhibitors eliminates the possibility that glycation
could be a major factor, since the inhibitors are
specific and do not alter the plasma or tissue levels
of hexose or glycation in the galactose-fed rat (Chiou
et al., 1980; Kern and Engerman, 1995; Robison et
al., 1989a, 1993). A complete prevention of cataracts
and essential prevention of diabetic-like retinopathy
has been documented in rats fed a 50% galactose
diet plus one of three different aldose reductase
inhibitors (AL-3152, sorbinil or tolrestat) for 24-28
months (Robison et al., 1989a, 1990c, 1993; Robison
and Laver, 1993; Sections 7-9).
Although supporting data has been abundant, some
concerns have been expressed regarding the
galactose-fed rat as a model of the full spectrum of
diabetic complications: (1) do retinal pericyte ghosts
occur in galactose-fed rats; (2) do the galactitol
a n d / o r glycation levels correspond to vessel
damage and degree of lesion prevention; (3) are the
microaneurysms in rat retinas equivalent to those
in humans; (4) why is retinopathy uncommon in
galactosemic patients; and (5) can the prevention
findings be repeated?

13.1. Retinal Pericyte Ghosts
The early occurrence of pericyte ghosts in any rat
model of diabetes has been questioned (Frank, 1994;
Frank and Das, 1992; Frank et al., 1983; Tilton et
al., 1986). Nevertheless, abundant evidence
supporting pericyte loss in rats has been presented by
several independent laboratories. Pericyte ghosts,
many of which have been documented by published
high resolution light and electron micrographs, have
been reported in retinal capillaries of various types
of diabetic rats (Cohen and Rosenmann, 1990; Kern
and Engerman, 1994; Kojima et al., 1975; Robison
et al., 1991b; Sima et al., 1985) and in the
galactose-fed rat model (Robison et al., 1989a,
1990c; Robison and Laver, 1993). Kern and
Engerman (1995) demonstrated pericyte ghosts
within 15 months in retinal capillaries of rats fed
either 30 or 50% galactose. Figure 5 demonstrates
that pericyte ghosts not only occur in galactose-fed
rats, but can be formed as early as 6 months after
administration of a 50% galactose diet.
13.2. Galactitol a n d / o r Glycation Levels
The limited measuring of polyol levels in
galactose-fed rats has raised concerns (Engerman
and Kern, 1993). Blood was the only tissue measured
in the original report of diabetic-like retinopathy
through the severe non-proliferative stage in a
galactose-fed rat. The average non-fasting blood
polyol was 36 mg/dl in the untreated rats, 2.9
mg/dl in the treated and less than 1.0 mg/dl in the
controls (Robison et al., 1989a, p. 2290). Although
total polyol rather than galactitol alone was reported,
it is well established that essentially all the blood
polyol is galactitol in galactose-fed rats (Dvomik,
1987). The remainder is sorbitol at a concentration of
< 1.0 mg/dl. Measurements in tissues other than
blood have been reported subsequently. The very
rapid galactitol accumulation, which occurs in lens
epithelium (Fig. 2B) is discussed in Section 12.4.
A major concern in the galactose-fed rat is that
the same levels of galactosemia be maintained in
both untreated and treated groups of animals
throughout the experiment. In the original
experiments on the galactose-fed rat model (Robison
et al., 1989a, 1990c), the blood galactose levels were
the same in both untreated and treated rats (216 and
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235 mg/dl), and were undetectable in controls at the
termination of the experiment (Robison et al.,
1989a). However, a much better assessment of
galactosemia is accomplished by measuring the
glycohemoglobin levels during the experiment. In a
more recent experiment (Robison et al., 1993),
glycohemoglobin levels measured at 6, 18 and 24
months demonstrated no statistically significant
differences between galactose-fed rats whether
untreated or treated with the aldose reductase
inhibitor AL-3152. A more rigorous monitoring of
glycohemoglobin levels was performed by Kern and
Engerman (1995) in their galactose-fed rats. Two
important findings were demonstrated: (1) that an
aldose reductase inhibitor (sorbinil) had no effect on
glycohemoglobin levels, and (2) that there was no
need to modify the feeding regimes ( a d libitum in
both) to maintain an equivalent level of
glycohemoglobin in untreated and treated galactosefed rats. These findings suggest that all studies,
which assure ad libitum feeding of a diet with a
constant per cent of galactose will maintain
comparable levels of glycohemoglobin regardless of
whether they receive an aldose reductase inhibitor or
not. However, the repeated monitoring of
glycohemoglobin levels serves as a double check on
feeding behavior, when performed.

13.3. Microaneurysms in Rat Retinas
Concerns were raised by investigators who have
been unable to demonstrate microaneurysms in rats
fed a 30% galactose diet for 21 months (Frank,
1991b, 1994; Frank and Das, 1992). Nevertheless,
the majority of evidence indicates that
microaneurysms do develop (Section 7), along with
the other lesions characteristic of diabetic retinopathy
through the mild proliferative stage (Figs 6-9).
Confirmation that pericyte ghosts, acellular
capillaries, hypercellular vessels (IRMA) and some
microaneurysms in retinas of galactose-fed rats do,
in fact, develop was recently reported by an
independent laboratory. Using either a 50% or a 30%
galactose diet (Kern and Engerman, 1995), multiple
diabetic-like capillary lesions were demonstrated after
15-26 months. Only the definition and interpretation
of microaneurysms differed slightly. A narrow
criterion for what was accepted as a true
microaneurysm was employed: the capillary
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aberration had to be saccular to be considered a
microaneurysm by Kern and Engerman (1995). The
fact that other types of microaneurysms occur in
humans, perhaps even more commonly than the
saccular type, was not taken into account. Recently,
the different types of microaneurysms in human
diabetics were quantified from retinal digest
preparations (Ghose et al., 1994). It was determined
that 17% of the microaneurysms were saccular, 24%
were irregularly shaped and 59% were spherical.
Although more representative data are needed, it
appears that the saccular type of microaneurysm is
not necessarily the predominant type in humans or
rats. The distinction between microaneurysms and
IRMA is somewhat ambiguous in rats, in which no
standard definitions have yet been formulated.
Therefore, the findings of Kern and Engerman (1995)~
are basically consistent with our earlier report
(Robison et al., 1989a) that most of the
microaneurysms of galactose-fed rats are fusiform,
cylindrical (tubular) or irregular in shape rather than
saccular. Even if many of the irregular
microaneurysms were classified as IRMA, this would
not invalidate the galactose-fed rat as a model of
human diabetic retinopathy because IRMA are among
the most predictive lesions of progression to
proliferative retinopathy (Davis, 1991; ETDRS,
19910.
Many of the microaneurysms in rats have more
capillary connections than the two which are thought
to be characteristic, representing the afferent and
efferent portions of a single capillary. However,
humans with diabetic retinopathy also commonly
exhibit microaneurysms with multiple capillary
connections in digest preparations. They have been
clearly documented by some investigators
(Fryczkowski and Sato, 1986; Fryczkowski et al.,
1991) and appear to be present in the micrographs
published by several others. Bloodworth (1962, Fig.
21, Bloodworth, 1964, plate X) demonstrated a
human microaneurysm with at least three clear
connections and a possible forth. Wolter (1961, Figs
12 and 13) also demonstrated microaneurysms with
three and four connecting capillaries, in addition to
several fibrous strands. The excellent scanning
electron micrographs presented by Fryczkowski et
al. (1991) leave no ambiguity. They demonstrate
human diabetic retinal microaneurysms with three
and four capillary connections. Therefore, contrary
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to previous reports (Frank and Das, 1992), it appears
that rats fed either a 30 or a 50% galactose diet are
reliable models for the complete spectrum of diabetic
retinopathies.

13.4. Galactosemia in Humans
Essentially all patients with congenital
galactosemia have cataracts, as would be predicted
from studies of galactose-fed rats. However, the
clinical manifestation of retinopathy in these patients
is uncommon, probably because galactosemia is
strictly controlled and/or the patients usually die
before significant retinal changes would be expected.

expected target tissue levels of inhibitor were not
obtained, probably due to a problem in sorbinil
administration. Possibly uneven mixing or inadequate
freshness of the sorbinil diet were factors. In any
case, the inadequate dosing must have continued for
at least 6 contiguous days during the experiment,
since cataracts are reversible within 5 days by sorbinil
treatment (Hu et al., 1983) or removal of the
galactose diet (Simard-Duquesne and Dvornik, 1973).
Regardless of how the aldose reductase inhibitor
studies might be interpreted, it is clear that the
galactose-fed rat as well as the galactose-fed dog, is
a useful model of diabetic retinopathy.
14. SUMMARY AND CONCLUSIONS

13.5. Can the Prevention Findings be Repeated?
Kern and Engerman (1995) confirmed that
galactose feeding induces increased tissue polyol,
and a concomitant diabetic-like retinopathy through
the severe non-proliferative stage, but they were
unable to demonstrate a prevention with the aldose
reductase inhibitor sorbinil. Nevertheless, several
studies have demonstrated an essential prevention of
all the galactose-induced retinal microanglopathies
using any one of three different aldose reductase
inhibitors (Robison and Laver, 1993, 1994). It is
important to note that the rat studies, which have
demonstrated a positive effect of aldose reductase
inhibitors in the retina (Sections 8 and 9), have
routinely found complete prevention of cataracts (no
sign of opacity by slit lamp, gross exam, or histology)
for at least 24 months in all galactose-fed rats treated
with most of the aldose reductase inhibitors tested,
including sorbinil. The only exception has been statil,
which delays rather than prevents cataracts (Robison
et al., 1992). By contrast, Kern and Engerman (1995)
were unable to completely prevent cataracts.
The failure to prevent cataracts suggests the key
to interpreting the negative results in the retina. The
lens, which retains all its cells throughout life,
provides an accurate history of any past irreversible
cellular insult, and thus serves as a good built-in
control against experimental errors (Section 8).
Sorbinil at the dose claimed is known to prevent
cataracts for up to 24 months in rats fed 50%
galactose (Dvornik, 1987; Robison and Laver, 1993,
1994). Cataract formation in the sorbinil-treated rats
(Kern and Engerman, 1995) indicates that the

Diabetic retinopathy is the major cause of
blindness in adults (20-74 yr-old) in the
industrialized countries. Whereas systemic diabetes
mellitus results from lowered availability a n d / o r
cellular recognition of insulin, the complications of
diabetes such as diabetic retinopathy are caused by
the chronic hyperglycemia itself. Although
conventional insulin therapy lowers blood glucose
levels enough to preserve life, it does not permit
complete euglycemia nor prevent the long-term
complications of chronic supernormal levels of blood
glucose. Recent extensive clinical trials demonstrate
that even intensive insulin treatment only delays
diabetic complications, and it causes a 2-3-fold
increase in severe hypoglycemia. This report presents
experimental animal evidence for the efficacy of a
novel approach to preventing diabetic complications,
which would be used in addition to conventional
insulin therapy, not to control blood glucose, but
instead, to decrease the toxic effects of hyperglycemia
on cells.
The studies were made possible by the creation of
a reliable and convenient animal model for diabetic
retinopathy - - the galaetose-fed rat. Probably the
earliest toxic effect of elevated glucose levels in
diabetic patients is increased aldose reductase
activity, which leads to an intracellular accumulation
of sorbitol, the polyol of glucose. By taking
advantage of the fact that aldose reductase has a
higher affinity for galactose than for glucose, much
higher levels of polyol (galactitol) were attained in
the cells of normal rats fed a 50% galactose diet than
occurs in diabetic rats or humans (Fig. 2). The

631

Aldose Reductase and Diabetic Retinopathy
extraordinarily high polyol level accelerated sugar
cataract formation and permitted the development o f
all stages of diabetic retinopathy through the mild
proliferative stage within 24 months in galactose-fed
rats (Figs 6 and 7) in contrast to diabetic rats, which
never show more than the early stages. The
galactose-fed rat model permits the dissociation of
the effects of polyol accumulation from those of
elevated blood glucose, insulin, and glycosylation
levels, as well as other metabolic or genetic factors
that might influence the development of diabetic
complications. Only polyol-related or glycationrelated complications should be manifest in untreated
galactose-fed rats and only glycation-related
complications should develop in galactose-fed rats
treated with an aldose reductase inhibitor. Since
three inhibitors of aldose reductase with very different
structures (Alcon 3152, sorbinil and tolrestat)
prevented diabetic-like retinopathy (Fig. 10) without
changing glycohemoglohin levels (Robison et al.,
1993), the activity of aldose reductase is probably
the initiating event of diabetic retinopathy. Whether
or not glycation could be involved as a secondary
factor remains to be established.
Substantial evidence indicates that abnormal
accumulation of sorbitol resulting from activation of
the enzyme aldose reductase of the polyol pathway is
not only the best candidate for the initiating event of
diabetic retinopathy, but also of many other ocular
complications of diabetes. Prevention of sorbitol
accumulation by oral administration of aldose
reductase inhibitors has prevented sugar cataract
formation, corneal edema, clouding and healing
defects in both diabetic and galactose-fed rat models
of diabetes. These findings identify a treatment that
should be beneficial in humans, if used to compliment
conventional insulin therapy. Aldose reductase
inhibitors would protect against the toxic effects o f
the relatively low, yet supernormal levels of glucose
that cannot be eliminated with insulin therapy.
However, treatment should begin early, long before
clinical signs o f the c o m p l i c a t i o n s ; d r u g
pharmacokinetics should be considered thoroughly;
and treatment should be continued on a long-term
basis in order to prevent complications which take a
long time to develop.
Acknowledgements--The authors wish to thank: Dr Carl Kupfer,
Director of the National Eye Institute, NIH, and Dr Jin H.
Kinoshita, Department of Ophthalmology, University of

California-Davis, for their continual encouragement; Dr Alec
Garner, Emeritus Professor of Pathology, University of London,
for carefully reviewing the manuscript; Dr Billie M. York, Jr,
Vice President of Research of Alcon Laboratories, Inc., for the
aldose reductase inhibitor AL-3152 and some of the funding; the
National Disease Research Interchange (Philadelphia, PA), the
Old Dominion Eye Bank (Richmond, VA), and the Rochester Eye
and Human Parts Bank (Rochester, NY) for donor eyes; Jaime E.
Dickerson, Jr and Sally Scheib of Alcon Lahoratories for technical
assistance; Anne Groome, Joseph HackeR, Jo¢l Glover, Evita
Bynum, Usha Tuscano, Bryan Dcrrickson, Bruce Sumlin, Paresh
Shah, Sanjay Shah, Matthew Oliva, Brian Feldman and Rudrani
Banik of the National Eye Institute for technical assistance and
manuscript preparation.

REFERENCES
Addison, D. J., Garner, A. and Ashton, N. (1970) Degeneration of
intramural pericytes in diabetic retinopathy. Br. reed. J. 1:
264-266.
Agrawal, P. K., Agarwal, L. P. and Tandon, H. D. (1966)
Experimental diabetic retinopathy in albino rats. Orient.
Archs Ophthal. 4: 68-76.
Aiello, L. M. (1994) Diagnosis, management, and treatment of
nonproliferative diabetic retinopathy and macular edema.
In: Principles and Practice of Ophthalmology, Clinical
Practice (D. M. Albert and F. A. Jakobeic, eds) pp.
747-760. W. B. Saunders Company, Philadelphia, PA.
Aiello, L. M., Rand, L. I., Sebestyen, J. G., Weiss, J. N.,
Bradbury, M. J., Wafai, M. Z. and Briones, J. C. (1985)
The eyes and diabetes. In: Joslin's Diabetes Mellitus (C.
R. Kahn and G. C. Weir, eds) pp. 600-634. Lea and
Febiger, Philadelphia, PA.
Akagi, Y. and Kador, P. F. (1990) Effect of aldose reductase
inhibitors on the progression of retinopathy in galactose-fed
dogs. Expl Eye Res. 50: 635-639.
Akagi, Y., Kador, P. F., Kuwabara, T. and Kinoshita, J. H. (1983)
Aldose reductase localization in human retinal mural cells.
Invest. Ophthalmol. Vis. Sci. 24: 1516-1519.
Akagi, Y., Terubayashi, H., MiUen, J., Kador, P. F. and Kinoshita,
1. H. (1986) Aldose reductase localization in dog retinal
mural cells. Curt. Eye Res. 5: 883-886.
Anand, R. and Tasman, W. S. (1994) Nonrhegmatogenousretinal
detachment. In: Retina, Volume 3: Surgical Retina (S. J.
Ryan and B. M. Glaser, eds) pp. 2463-2488. The C. V.
Mosby Company, St Louis, Missouri.
Archer, D. B. (1976) Neovascularization of the retina. Trans.
ophthal. Soc. U.K. 96: 471-493.
Archer, D. B. (1977) Intraretinal, preretinal, and subretinal new
vessels. Trans. ophthal. Soc. U.~ 97: 449-456.
Archer, D. B., Amoaku, W. M. IC and Gardiner, T. A. (1991)
Radiation retinopathy - - Clinical, histopathologicai,
ultrastructural and experimental correlations. Eye 5: 239251.
Ashton, N. (1949) Vascular changes in diabetes with particular
reference to the retinal vessels. Preliminary report. Br. J.
Ophthal. 33: 407-420.

632

W. G. Robison et al.

Ashton, N. (1950) Injection of the retinal vascular system in the
enucleated eye in diabetic retinopathy. Br. J. OphthaL 34:
38-41.
Ashton, N. (1953) Arteriolar involvement in diabetic retinopathy.
Br. J. Ophthal. 37: 282-292.
Ashton, N. (1959) Diabetic retinopathy. A new approach. Lancet
2: 625-630.
Ashton, N. (1963) Studies of the retinal capillaries in relation to
diabetic and other retinopathies. Br. J. Ophthal. 47: 521538.
Ashton, N. (1970) Pathophysiology of retinal cotton-wool spots.
Br. med. Bull. 26: 143-150.
Ashton, N. (1971) Diabetic Retinopathy. Some current concepts.
In: Proc. Int. Symp. Fluorescein Angiography. pp. 334345. Karger, Basel, Switzerland.
Ashton N. (1974) Vascular basement membrane changes in
diabetic retinopathy. Br. J. Ophthal. 58: 344-366.
Ashton N. (1983) Pathogenesis of diabetic retinopathy. In:
Diabetic Retinopathy (H. L. Little, R. L Jack, A. Patz and
P. H. Forsham, eds) pp. 85-106. Thieme-Stratton Inc.,
New York.
Ashton, N. and Harry, J. (1963) The pathology of cotton wool
spots and cytoid bodies in hypertensive retinopathy and
other diseases. Trans. ophthal. Soc. U.K. 83: 91-114.
Ashton, N. and Tripathi, R. (1975) Perivascular and intervascular
reticular fibers of the retina. Am. J. Ophthal. 80: 337-359.
Ballantyne, A. J. (1945) Retinal changes associated with diabetes
and with hypertension. Archs Ophthal. 33: 97-105.
Ballantyne, A. J. and Loewenstein, A. (1944) Retinal
microaneurysms and punctate haemorrhages. Br. J.
Ophthal. 28: 593-598.
Banting, F. G. and Best, C. H. (1922) The internal secretion of the
pancreas. J. Lab. din. Med. 7: 251-266.
Baynes, J. W. (1991) Role of oxidative stress in development of
complications in diabetes. Diabetes 40: 405-412.
Bedell, A. J. (1939) Diseases of the fundus and optic nerve. 1.
The fundus changes in two hundred and five diabetics.
Trans. ophthaL Soc. U.K. 59: 219-230.
Benson, W. E., Brown, G. C. and Tasman, W. (1988) In: Diabetes
and Its Ocular Complications. W. B. Saunders Company,
Philadelphia, PA.
Bloodworth, J. M. B. Jr (1962) Diabetic retinopathy. Diabetes 2:
1-22.
Bloodworth, J. M. B. Jr (1963) Diabetic microangiopathy.
Diabetes 12: 99-114.
Bloodworth, J. M. B. Jr (1964) Histochemistry and electron
microscopy of diabetic retinopathy. In: Small Blood Vessel
Involvement in Diabetes Mellitus (M. D. Siperstein, A. R.
Colwell, St. and K. Meyer, eds) pp. 81-87. American
Institute of Biological Sciences, Washington DC.
Bloodworth, J. M. B. Jr (1967) Fine structure of retina in human
and canine diabetes mellitus. In: Vascular Complications
of Diabetes Mellitus, with Special Emphasis on
Microangiopathy of the Eye (S. J. Kimura and W. M.
Caygill, eds) pp. 73-98. C. V. Mosby Company, St Louis,
Missouri.
Bloodworth, J. M. B. Jr and Molitor, D. L. (1965) Ultrastructural

aspects of human and canine diabetic retinopathy. Invest.
Ophthalmol. Via. Sci. 4: 1037-1048.
Bobik, A. and Canlpbell, J. H. (1993) Vascular derived growth
factors: ceU biology, pathophysiology, and pharmacology.
Pharmac. Rev. 45: 1-42.
Boot-Handford, R. and Heath, H. (1980) Identification of fructose
as the retinopathic agent associated with the ingestion of
sucrose-rich diets in the rat. Metabolism 29: 1247-1252.
Bresuick, G. H. (1994) Nonproliferative diabetic retinopathy. In:
Reana, Volume 2: Medical Retina (S. J. Ryan, A. P.
Schachat and R. B. Murphy, eds) pp. 1277-1318. C. V.
Mosby Company, St Louis. Missouri.
Bresnick, G. H., Engerman, R., Davis, M. D., de Venccia, G. and
Myers, F. L (1976) Patterns of ischemia in diabetic
retinopathy. Trans. Am. Acad. OphthaL Oto-lar. 81: 694709.
Bresuick" G. H., Korth, K., Oroo, A. and Palm, M. (1984)
Electroretinographic oscillatory potentials predict
progression of diabetic retinopathy. Preliminary report.
Archa Ophthal. 102: 1307-1311.
Brown, G. C. (1994a) Ocular ischemic syndrome. In: Retina,
Volume 2: Medical Retina (S. J. Ryan, A. P. Schachat and
R. B. Murphy, eds) pp. 1515-1527. C. V. Mosby
Company, St Louis, Missouri.
Brown, G. C. (1994b) Retinal arterial obstructive disease. In:
Retina, Volume 2: Medical Retina (S. J. Ryan, A. P.
Schachat and R. B. Murphy, cds) pp. 1361-1377. C. V.
Mosby Company, St Louis, Missouri.
Brown, G. C. and Benson, W. E. (1984) The fundus manifestations
of malignant hypertension. Trans. Am. Acad. Ophthal.
Oto-lar. 37: 19-25.
Brown, G. C., Brown, M. M., Hiller, T., Fischer, D., Bcnson, W.
E. and Magargal, L. E. (1985) Cotton-wool spots. Retina
5: 206-214.
Brownlee, M. (1990) Advanced products of nonenzymatic
glycosylation and the pathogenesis of diabetic
complications. In: EUenberg and Rifkin's Diabetes
Mellitus: Theory and Practice (H. Rifldn and D. Porte Jr,
eds) pp. 279-291. Forth Edition. Elsevier Science
Publishers BV, New York.
Brownlce, M., Cerami, A. and Vlassara, H. (1988) Advanced
glycosylation end products in tissue and the biochemical
basis of diabetic complications. New Engl. J. Med. 318:
1315-1321.
Bunn, H. F., Gabbay, K. H. and Gallop, P. M. (1978) The
glycosylation of hemoglobin: relevance to diabetes
mellitus. Science (USA) 200: 21-27.
Buzney, S. M., Frank, R. N., Varma, S. D., Tanishima, T. and
Gabbay, K. H. (1977) Aldose reductase in retinal mural
cells. Invest. Ophthalmol. Via. Sci. 16: 392-396.
Carlson, E. C. (1989) Human retinal capillary basement membrane
leaflets are morphologically distinct: a correlated TEM and
SEM analysis. Expl Eye Res. 49: 967-981.
Carlson, E. C. and Bjork" N. L (1990) SEM and TEM analyses of
isolated human retinal microvessel basement membranes
in diabetic retinopathy. Anat. Rec. 226: 295-306.
Casey, R., Li, W. W. and Adamis, A. P. (1994) Ocular

Aldose Reductase and Diabetic Retinopathy
angiogenesis. In: Principles and Practice of
Ophthalmology (D. M. Albert and F. A. Jakobiec, eds) pp.
1100-1107. W. B. Saunders Company, Philadelphia, PA.
Chakrabarti, S., Sima, A. A. F., Tze, W. J. and Tai, J. (1987)
Prevention of diabetic retinal capillary pericyte
degeneration and loss by pancreatic islet allograft. Curr.
Eye Res. 6: 649-658.
Chaudhuri, P. R., Austin, D. J. and Rosenthal, A. R. (1981)
Treatment of radiation retinopathy. Br. J. Ophthal. 65:
623-625.
Cherian, M. and Abraham, E. C. (1993) Glycation of human lens
crystallins: effect of age and aspirin treatment. Ophthal.
Res. 25: 349-354.
Chiou, S., Chylack, L. T. Jr, Bunn, H. F. and Kinoshita, J. H.
(1980) Role of nonenzymatic glycosylation in experimental
cataract formation. Biochem. biophys. Res. Commun. 95:
894-901.
Cogan, D. G. (1974) Diabetes. Ophthalmic manifestations of
systemic vascular disease. In: Major Problems in Internal
Medicine (L. H. Smith Jr, ed.) pp. 81-180. Vol. III. W.B.
Saunders Co., Philadelphia, PA.
Cogan, D. G. and Kuwahara, T. (1963) Capillary shunts in the
pathogenesis of diabetic retinopathy. Diabetes 12: 293300.
Cogan, D. G. and Kuwabara, T. (1967a) The mural cell in
perspective. Archs Ophthal. 78: 133-139.
Cogan, D. G. and Kuwabara, T. (1967b) Ocular microangiopathy
in diabetes. In: Vascular Complications of Diabetes
Mellitus, with Special Emphasis on Microangiopathy of the
Eye (S. J. Kimura and W. M. CaygiU, eds) pp. 53-72. C.
V. Mosby Co., St Louis, Missouri.
Cogan, D. G., Toussaint, D. and Kuwabara, T. (1961) Retinal
vascular patterns. IV. Diabetic retinopathy. Archs Ophthal.
66: 366-378.
Cohen, A. M. and Rosenmann, E. (1990) In: The Cohen Diabetic
Rat. Karger, Basel, Switzerland.
Cohen, S. B. and van Houten, P. A. (1994) Hemoglobinopathies.
In: Retina, Volume 2: Medical Retina (S. J. Ryan, A. P.
Schachat and R. B. Murphy, eds) pp. 1465-1472. C. V.
Mosby Company, St Louis, Missouri.
Cohen, A. M., Michaelson, I. C. and Yanko, L. (1972) Retinopathy
in rats with disturbed carbohydrate metabolism following a
high sucrose diet. I. Vascular changes. Arm J. Ophthal.
73: 863-869.
Crocker, D. J., Murad, T. M. and Geer, J. C. (1970) Role of the
pericyte in wound healing. An ultrastructural study. Expl
Mol. Path. 13: 51-65.
Cunha-Vaz, J. G. (1991) Natural history of diabetic retinopathy.
In: Diabetic Complication. Epideraiology and Pathogenic
Mechanisms (D. Andreani, J. L. Guerignian, G. E. Striker
and F. G. Conti, eds) pp. 171-180. Raven Press, New
York.
Cunha-Vaz, J., de Abreu, J. R. F., Campos, A. J. and Figo, G. M.
(1975) Early breakdown of the blood-retinal barrier in
diabetes. Br. J. Ophthal. 59: 649-656.
Danis, R. P. and Wallow, H. L. (1986) HRT/trypsin technique
for studies of the retinal vascolature. Invest. Ophthalmol.
Vis. Sci. 27: 434-437.

633

Das, A., Frank, R. N., Zhang, N. L. and Samadani, E. (1990)
Increases in collagen type IV and laminin in galactoseinduced retinal capillary basement membrane thickening
- - Prevention by an aldose reductase inhibitor. Expl Eye
Res. 50: 269-280.
Datiles, M., Fukui, H., Kuwahara, T. and Kinoshita, J. H. (1982)
Galactose cataract prevention with sorbinil, an aldose
reductase inhibitor: a light microscopic study. Invest.
Ophthalmol. Vis. Sci. 22: 174-179.
Davis, M. D. (1988) Diabetic retinopathy: a clinical overview.
Diabetes~Metabolism Reviews 4: 291-322.
Davis, M. D. (1991) Retinopathy classification and progression
rates. In: Aldose Reductase lnhibitors. NEI-Juvenile
Diabetes Foundation Workshop, September 4-5, 1990.
NIH Publ. #91-3114', pp. 11-23.
Davis, M. D. (1994) Proliferative diabetic retinopathy. In: Retina,
Volume 2: Medical Retina (S. J. Ryan, A. P. Schachat and
R. B. Murphy, eds) pp. 1319-1359. C. V. Mosby
Company, St Louis, Missouri.
Davis, M. D., Norton, E. W. D. and Myers, F. L. (1969) The
Airlie classification of diabetic retinopathy. In: Symposium
on the Treatment of Diabetic Retinopathy (M. F. Goldberg
and S. L. Fine, eds) pp. 7-22. U.S. Public Health Service
Publication No. 1890. U.S. Government Printing Office,
Washington DC.
D'Amore, P. A. (1994) Mechanisms of retinal and choroidal
neovascularization. Invest. Ophthalmol. Vis. Sci. 35:
3974-3979.
de Oliveira, F. (1966) Pericytes in diabetic retinopathy. Br. J.
Ophthal. 50: 134-143.
de Venecia, G., Davis, M. and Engerman, R. (1976)
Clinocopathologic correlations in diabetic retinopathy. I.
Histology and fluorescein angiography of microaneurysms.
Archs Ophthal. 94: 1766-1773.
Deruaz, J. P. (1969) Etude histo-pathologique de la vascularisation
retinienne par la methode de la digestion enzymatique.
Documenta ophth. 25: 282-359.
Destro, M. and Gragoudas, E. S. (1994) Arterial occlusions. In:
Principles and Practice of Ophthalmology. Clinical
Practice (D. M. Albert and F. A. Jakobiec, eds) pp.
727-735. Vol. 2. W. B. Saunders Company, Philadelphia,
PA.
Diabetes Control and Complications Trial (DCCI') Research Group
(1993) The effect of intensive treatment of diabetes on the
development and progression of long-term complications
in insulin-dependent diabetes mellitus. New Engl. J. Med.
329: 977-986.
Diabetic Retinopathy Study (DRS) Research Group (1976)
Preliminary report on effects of photocoagulation therapy.
Am. J. Ophthal. 81: 383-396.
Diabetic Retinopathy Study (DRS) Research Group (1978)
Photocoagulation treatment of proliferative diabetic
retinopathy: the second report of Diabetic Retinopathy
Study Findings. Ophthalmology 85: 210-226.
Diabetic Retinopathy Study (DRS) Research Group (1981a)
Diabetic retinopathy study, Report Number 6. Design,
methods, and baseline results. Invest. Ophthalmol. VIS.
Sci. 21: 149-209.

634

W. G. Robison et al.

Diabetic Retinopathy Study (DRS) Research Group (1981b)
Diabetic retinopathy study, Report Number 7. Modification
of the Airiie House classification of diabetic retinopathy.
Invest. Ophthalmol. Vis. Sci. 21: 210-226.
Dickerson, J. E. Jr and Lou, M. F. (1990) Micro-quantitation of
lens myo-inositol by anion exchange chromatography.
Curt. Eye Res. 9" 201-205.
Doi, T., Hattori, M., Agodoa, L. Y. C., Sato, T., Yoshida, H.,
Striker, L. J. and Striker, G. E. (1990) Glomerular lesions
in nonobese diabetic mouse: before and after the onset of
hyperglycemia. Lab. Invest. 63: 204-212.
Duke, J. R., Wilkinson, C. P. and Sigelman, S. (1968) Retinal
microaneurysms in leukaemia. Br. J. Ophthal. 52: 368374.
Dvornik, D. (1987) In: Aldose Reductase Inhibition: An Approach
to the Prevention of Diabetic Complications (D. Porte, ed.)
Biomedical Information Corporation, McGraw-Hill, New
York.
Dvornik, D., Millen, J., Hicks, D., Cayen, M. and Sredy, J. (1988)
The pharmacokinelics of aldose reduetase inhibitors. In:
Polyol Pathway and Its Role in Diabetic Complications
(N. Sakamoto, J. H. Kinoshita, P. F. Kador and N. Hotta,
eds) pp. 61-71. Elsevier Science Publishers BV
(Biomedical Division), Amsterdam, Netberlands.
Dvornik, D., Millen, J., Hicks, D. R. and Kraml, M. (1994)
Tolrestat pharmacokinetics in rat peripheral nerve. J. Diab.
Comp. 8: 18-26.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research
Group (1991a) Early treatment diabetic retinopathy study
design and baseline patient characteristics. ETDRS Report
Number 7. Ophthalmology 98: 741-756.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research
Group (1991b) Effects of aspirin treatment on diabetic
retinopathy. ETDRS Report Number 8. Ophthalmology
98: 757-765.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research
Group (1991c) Early photocoagnlation for diabetic
retinopathy. ETDRS Report Number 9. Ophthalmology
98: 766-785.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research
Group (1991d) Grading diabetic retinopathy from
stereoscopic color Inndus photographs - - An extension of
the modified Airlie House classification. ETDRS Report
Number 10. Ophthalmology 98: 786-806.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research
Group (1991e) Classification of diabetic retinopathy from
fluorescein angiograms. ETDRS Report Number 11.
Ophthalmology 98: 807-822.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research
Group (19910 Fundus photographic risk factors for
progression of diabetic retinopathy. ETDRS Report
Number 12. Ophthalmology 98: 823-833.
Early Treatment Diabetic Retinopethy Study (ETDRS) Research
Group (1991g) Fluorescein angiographic risk factors for
progression of diabetic retinopathy. ETDRS Report
Number 13. Ophthalmology 98: 834-840.
Engerman, R. L. and Bloodworth, J. M. B. Jr (1965) Experimental
diabetic retinopathy in dogs. Archs Ophthal. 73: 205-210.

Engerman, R. L. and Kern, T. S. (1984) Experimental galactosemia
produces diabetic-like retinopathy. Diabetes 33: 97-100.
Engerman, R. L. and Kern, T. S. (1987) Progression of incipient
diabetic retinopathy during good glycemic control.
Diabetes 36: 808-812.
Engerman, R. L. and Kern, T. S. (1989) Determinants of
experimental diabetic retinopathy. In: Diabetes 1988 (R.
Lark.ins, P. Zimmer and D. Chisholm, eds) pp. 221-224.
Elsevier Science Publishers BV (Biomedical Division),
Netherlands.
Engerman, R. L. and Kern, T. S. (1991) Aldose roductase and
retinopathy - - current controversies. In: Diabetes 1991:
Proceedings of the 14th International Diabetes Federation
Congress. Washington DC, 23-28 June 1991 (H. Rifkin, J.
A. ColweU and S. I. Taylor, eds) pp. 462-465. Elsevier
Science Publishers BV, Amsterdam.
Engerman, R. L. and Kern, T. S. (1993) Aldose reductase inhibition
falls to prevent tctinopathy in diabetic and galactosemic
dogs. Diabetes 42: 820-825.
Engerman, R. L., Bloodworth, J. M. B. Jr and Nelson, B. S.
(1977) Relationship of microvascular disease in diabetes to
metabolic control. Diabetes 26: 760-769.
Engerman, R. L., Finkelstein, D., Agnirre, G., Diddie, K. R., Fox,
R. R., Frank, R. N. and Varma, S. D. (1982) Ocular
complications. Diabetes 31 (Suppl. 1): 82-88.
Engerman, R. L., Pfaffenbach, D. and Davis, M. D. (1967) Cell
turnover of capillaries. Lab. Invest. 17: 738-743.
Erickson, L. A., Fici, G. J., Lund, J. E., Boyle, T. P., Polites, H.
G. and Morotti, K. R. (1990) Development of venous
occlusions in mice transgenic for the plasminogen activator
inhibitor-1 gene. Nature 346: 74-76.
Feke, G. T., Buzney, S. M., Ogasawara, H., Fujio, N., Goger, D.
G., Spack, N. P. and Gabbay, IC H. (1994) Retinal
circulatory abnormalities in type I diabetes. Invest.
Ophthalmol. Vis. Sci. 35: 2968-2975.
Fischer, F. and G~rtner, J. (1983) Morphometric analysis of basal
laminae in rats with long-term streptozotocin diabetes 1. II.
Retinal capillaries. Expl Eye Res. 37: 55-64.
Fong, D. S. and Rand, L. I. (1994) Epidemiology of diabetic
retinopathy. In: Principles and Practice of Ophthalmology
(D. M. Albert and F. A. Jakobiec, eds) pp. 1285-1296. W.
B. Sannders Company, Philadelphia, PA.
Forrester, J. V., Shafie¢, A., SchrSder, S., Knott, R. and McIntosh,
L. (1993) The role of growth factors in proliferative diabetic
retinopathy. Eye 7: 276-287.
Frank, R. N. (1991a) New concepts in the pathogenesis of diabetic
retinopathy. In: Diabetes 1991: Proceedings of the 14th
International Diabetes Federation Congress. Washington
DC, 23-28 June 1991 (H. Rifkin, J. A. Colwell and S. I.
Taylor, eds) pp. 466-473. Elsevier Science Publishers BV,
Amsterdam.
Frank, R. N. (1991b) On the pathogenesis of diabetic retinopathy.
A 1990 update. Ophthalmology 96: 586-593.
Frank, R. N. (1994) Etiologic mechanisms in diabetic retinopathy.
In: Retina, Volume 2: Medical Retina (S. J. Ryan, A. P.
Schachat and R. B. Murphy, eds) pp. 1243-1275. C. V.
Mosby Company, St Louis, Missouri.
Frank, R. N. and Das, A. (1992) Pathogenic mechanisms in

Aldose Reductase and Diabetic Retinopathy
diabetic eye disease. In: Ocular Problems in Diabetes
Mellitus (S. S. Feman, ed.) pp. 95-133. Blackwell
Scientific Publications, Boston, Massachusetts.
Frank, R. N., Keirn, R. J., Kennedy, A. and Frank, K. W. (1983)
Galactose-induced retinal capillary basement membrane
thickening: prevention by sorbinil. Invest. Ophthalmol.
Vis. Sci. 24: 1519-1524.
Friedenwald, J. S. (1949) A new approach to some problems of
retinal vascular disease. Am. J. Ophthal. 32: 487-498.
Friedenwald, J. S. (1950) Diabetic retinopathy. Ant J. Ophthal.
33: 1187-1199.
Fryczkowski, A. W. and Sato, S. E. (1986) Scanning electron
microscopy of the ocular vasculature in diabetic
retinopathy. Contemporary Ophthalmic Forum 4: 39-50.
Fryczkowski, A., Chambers, R. B., Craig, E. J., Walker, J. and
Davidorf, F. H. (1991) Scanning electron microscopic
study of microaneurysms in the diabetic retina. Ann.
Ophthal. 23: 130-136.
Fu, M., Wells-Knecht, IC J., Blackledge, J. A., Lyons, T. J.,
Thorpe, S. R. and Baynes, J. W. (1994) Glycation,
glycoxidation, and cross-linking of collagen by glucose.
Kinetics, mechanisms, and inhibition of late stages of the
Maillard reaction. Diabetes 43: 676-683.
Fukushi, S., Merola, L. O. and Kinoshita, J. H. (1980) Altering
the course of cataracts in diabetic rats. Invest. Ophthalmol.
Vis. Sci. 19: 313-315.
Gardner, T. W. and Blankenship, G. W. (1994) Proliferative
diabetic retinopathy: principles and techniques of surgical
treatment. In: Retina, Volume 3: Surgical Retina (S. J.
Ryan and B. M. Glaser, eds) pp. 2407-2437. C. V. Mosby
Company, St Louis, Missouri.
Garner, A. (1970) Pathology of diabetic retinopathy. Br. reed.
Bull. 26: 137-142.
Garner, A. (1994) Vascular diseases. In: Pathobiology of Ocular
Disease. A Dynamic Approach. Part B (A. Garner and G.
K. Klintworth, eds) pp. 1625-1710. Second Edition.
Marcel Dekker Inc., New York.
Garner, A. (1993) Histopathology of diabetic retinopathy in man.
Eye 7: 250-253.
Geisen, K., Utz, R., Gr6tsch, H., l.amg, H. J. and Nimmesgern, H.
(1994) Sorbitol-accumulating pyrimidine derivatives. Drug
Res. 44: 1032-1043.
Gepts, W. and Toussaint, D. (1967) Spontaneous diabetes in dogs
and cats. Diabetologia 3: 249-265.
Ghose, R. P., Marsico, N. P., Whitaker, T. E., Kellum, K. and
FryeT_kowski, A. W. (1994) Vascular changes in diabetic
retina - - Modified trypsin-digestion technique. Invest.
Ophthalmol. Vis. Sci. 35 (Suppl.): 1596.
Gibbs, G. E., Wilson, R. B. and Ho, C. K. (1969) Experimental
diabetes in the monkey. Proceedings of the 2nd
International Congress Primat. 3: 169-173.
Glaser, B. M. (1994a) Extracellular modulating factors and the
control of intraocular neovascularization: an overview. In:
Retina, Volume 3: Surgical Retina (S. Ryan and B. M.
Glaser, eds) pp. 2395-2406. C. V. Mosby Company, St
Louis, Missouri.
Glaser, B. M. (1994b) Surgery for proliferative vitreoretinopathy.
In: Retina, Volume 3: Surgical Retina (S. J. Ryan and B.

635

M. Glaser, eds) pp. 2265-2280. C. V. Mosby Company, St
Louis, Missouri.
Goldberg, M. F. (1976) Retinal vaso-occlusion in sickling
hemoglobinopathies. Birth Defects: Original Article Series
12: 475-515.
Goldberg, M. F. and Fine, S. L. (eds) (1969) Symposium on the
Treatment of Diabetic Retinopathy, DHEW Publ. No. 1890.
U.S. Dept. of Health, Education and Welfare, Arlington,
VA.
Gonz~lez, R. G., Barnett, P., Aguayo, J., Cheng, H. and Chylack,
L. T. Jr (1984) Direct measurement of polyol pathway
activity in the ocular lens. Diabetes 33: 196-199.
Grant, M., Mames, R. N., Fitzgerald, C., Ellis, E. A., Caballero,
S., Chegini, N. and Guy, J. (1993) Insulin-like growth
factor-I as an angiogenic agent, in vivo and in vitro
studies. Ann. N.Y. Acad. Sci. 692: 230-242.
Green, W. R., Quigley, H. A., de la Cruz, Z. and Cohen, B.
(1980) Parafoveal retinal telangiectasis, light and electron
microscopy studies. Trans. ophthal. Soc. U.K. 100: 162170.
Hamilton, A. M., Koimer, E. M., Rosen, D. and Bowbyes, J. A.
(1974) Retinal and choroidal blood flow problems. Proc.
R. Soc. Med. 67: 1045-1054.
Hammes, H. P., Martin, S., Federlin, K., Geisen, K. and Brownlee,
M. (1991) Aminoguanidine treatment inhibits the
development of experimental diabetic retinopathy. Proc.
natn. Acad. Sci. U.&A. 88: 11555-11558.
Hansen, B. C., Bodkin, N. L., Jen, K. C. and Ortmeyer, H. K.
(1991) Primate models of diabetes. In: Diabetes 1991:
Proceedings 14th International Diabetes Federation
Congress. Washington DC, 23-28 June 1991 (H. Ritkin, J.
A. Colwell and S. I. Taylor, eds) pp. 587-590. Elsevier
Science Publishers BV, Amsterdam.
Hansen, B. C., Ortmeyer, H. IC and Bodkin, N. L. (1994)
Obesity, insulin resistance, and noninsulin-dependent
diabetes mellitus in aging monkeys: implications for
NIDDM in humans. In: Lessons from Animal Diabetes (E.
Shafrir, ed.) (in press).
Hatchell, D. L. and Sinclair, S. H. (1994) Role of lcukocytes in
diabetic retinopathy. In: Physiology and Pathophysiology
of Leukocyte Adhesion (N. Granger and G. W. SchmidSchoenbein, eds) Oxford University Press, London (in
press).
Hatchell, D. L., Toth, C. A., Barden, C. A. and Saloupis, P.
(1994a) Diabetic retinopathy in a cat. Expl Eye Res.
(submitted).
HatcheU, D. L., Wilson, C. A. and Saloupis, P. (1994b) Neutrophils
plug capillaries in acute experimental retinal ischemia.
Microvasc. Res. 47: 344-354.
Hayman, S. and Kinoshita, J. H. (1965) Isolation and properties of
lens aldose reduetase. J. biol. Chem. 240: 877-882.
Hayreh, S. S. (1970) Post-radiatinn retinopathy, A fluroescence
fundus angiographic study. Br. J. Ophthal. 54: 705-714.
Henkind, P. (1966) Ballotini occlusion of retinal arteries, Collateral
vessels. Br. J. Ophthal. 50: 482-495.
Hohman, T. C., Nishimura, C. and Robison, W. G. Jr. (1989)
Aidosc reductase and polyol in cultured pericytes of human
retinal capillaries. Expl Eye Res. 48: 55-60.

636

W. G. Robison et al.

He, T., Dailies, M. and Kinoshita, J. H. (1983) Reversal of
galactose cataract with sorbinil in rats. Invest. Ophthalmol.
Vis. Sci. 24: 640-644.
Irvine, A. R. and Wood, I. S. (1987) Radiation retinopathy as an
experimental model for ischemic proliferative retinopathy
and rubeosis iridis. Am` J. Ophthal. 103: 790-797.
James, W. A. Jr (1980) Historical aspects of diabetic retinopathy.
In: Diabetic Renal - - Retinal Syndrome (E. A. Friedman
and F. A. L'Esperance, Jr, eds) pp. 27-42. Grune and
Stratton, New York.
Jonasson, O., Jones, C. W., Bauman, A., John, E., Manaligod, J.
and Tso, M. O. M. (1985) The pathophysiology of
experimental insulin-deficient diabetes in the monkey:
implications for pancreatic transplantation. Ann. Surg. 201:
27-39.
Kador, P. F. (1990) Preventive medicine: the contribution of
pharmaceuticals to better health. Prevention of ocular
diabetic complications by aldose reductase inhibitors. Swiss
Pharma 12: 33-38.
Kador, P. F., Akagi, Y., Terubayashi, H., Wyman, M. and
Kinoshita, J. H. (1988) Prevention of perieyte ghost
formation in retinal capillaries of galactose-fed dogs by
aldose reductase inhibitors. Archs Ophthal. 106: 10991102.
Kador, P. F., Akagi, Y., Takahashi, Y., Ikebe, H., Wyman, M. and
Kinoshita, J. H. (1990) Prevention of retinal vessel changes
associated with diabetic retinopathy in galactose-fed dogs
by aldose reductase inhibitors. Archs Ophthal. 108: 13011309.
Kador, P. F., Takahashi, Y., Sato, S. and Wyman, M. (1994)
Amelioration of diabetes-like retinal changes in galactosefed dogs. Prey. Med. 23: 717-721.
Karasik, A. and Hattori, M. (1994) Use of animal models in the
study of diabetes. In: Joslin's Diabetes Mellitus (C. R.
Kahn and G. C. Weir, eds) pp. 317-350. Lea and Febiger,
Philadelphia, PA.
Keith, N., Wagener, H. P. and Barker, N. W. (1939) Some
different types of essential hypertension: their course and
prognosis. Am. J. Med. Sci. 197: 332-343.
Kemper, C. and Dvornik, D. (1986) Prevention of neural
myoinositol depletion in diabetic rats by aldose reductase
inhibition with tolrestat (42372) Proc. Soc. exp. Biol. MecL
182: 505-510.
Kern, T. S. (1991) Dog model for diabetic retinopathy and
nephropathy. In: Aldose Reductase lnhibitors. NEIJuvenile Diabetes Foundation Workshop. NIH Publ. #913114 (National Eye Institute and Juvenile Diabetes
Foundation, eds) pp. 65-73. National Institutes of Health,
Bethesda, MD.
Kern, T. S. and Engerman, R. L. (1985) Hexitol production by
canine retinal microvessels. Invest. Ophthalmol. Vis. Sci.
26: 382-384.
Kern, T. S. and Engerman, R. L. (1991) Retinal polyol and
myo-inositol in galactosemic dogs given an aldosereductase inhibitor. Invest. Ophthalmol. Vis. Sci. 32:
3175-3177.
Kern, T. S. and Engerman, R. L. (1994) Comparison of retinal

lesions in alloxan-diabetic rats and galactose-fed rats. Curr.
Eye Res. 13: 863-867.
Kern, T. S. and Engerman, R. L. (1995) Galactose-induced retinal
microangiopathy in rats. Invest. Ophthalmol. Vis. Sci. 36:
490-496.
King, G. L. and Banskota, N. K. (1994) Mechanisms of diabetic
microvascular complications. In: Joslin's Diabetes Mellitus
(C. R. Kahn and G. C. Weir, ¢ds) pp. 631-647. Lea and
Fobiger, Philadelphia, PA.
Kinoshita, J. H. and Nishimura, C. (1988) The involvement of
aldose reductase in diabetic complications. Diabetes/
Metabolism Reviews 4: 323-337.
Kinoshita, J. H., Datiles, M. G., Kador, P. F. and Robison, W. G.
Jr (1990) Aldose reductase and diabetic eye complications.
In: Ellenberg and Rifkin's Diabetes Mellitus. Theory and
Practice (H. Rifkin and D. Porte Jr, eds) pp. 264-278.
Forth Edition. Elsevier Science Publishers BV, New York.
Kiagshron, M. and D'Amore, P. A. (1991) Regulators of
angiogenesis. A. Rev. Physiol. 53: 217-239.
Klein, R. and Klein, B. E. K. (1985) Vision disorders in diabetes.
In: Diabetes in America. Diabetes Data Compiled 1984.
NIH Publ. #85-1464 (H. R. Harris, ed.), pp. XIII.1XIII.36. U.S. Public Health Service, Bethesda, MD.
Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D. and DeMets,
D. L. (1984a) The Wisconsin epidemiologic study of
diabetic retinopathy. II. Prevalence and risk of diabetic
retinopathy when age at diagnosis is less than 30 years.
Archs OphthaL 102: 520-526.
Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D. and DeMets,
D. L. (1984b) The Wisconsin epidemiologic study of
diabetic retinopathy. IlL Prevalence and risk of diabetic
retinopathy when age at diagnosis is 30 or more years.
Archs Ophthal. 102: 527-532.
Klein, R., Klein, B. K., Moss, S. E., Davis, M. D. and DeMets, D.
L. (1988) Glycosylated hemoglobin predicts the incidence
and progression of diabetic retinopathy. J. Am. med. Ass.
260: 2864-2871.
Kohner, E. M. and Dollery, C. T. (1969) The natural history of
diabetic retinopathy. In: Symposium on the Treatment of
Diabetic Retinopathy (M. F. Goldberg and S. L. Fine, eds)
pp. 65-79. U.S. Public Health Service Publication No.
1890. U.S. Government Printing Office, Washington DC.
Kohner, E. M. and Henkind, P. (1970) Correlation of fluorescein
angiogram and retinal digest in diabetic retinopathy. Am.
J. Ophthal. 69: 403-414.
Kohner, E. M., Dollery, C. T. and Bulpitt, C. J. (1969) Cotton-wool
spots in diabetic retinopathy. Diabetes 18: 691-704.
Kohner, E. M., Hamilton, A. M., Joplin, G. F. and Fraser, T. R.
(1976) Florid diabetic retinopathy and its response to
treatment by photocoagulation or pituitary ablation.
Diabetes 25: 104-110.
Kojima, K., Harada, T., Sugita, G. and Miyake, S. (1975) On the
electron microscopic findings on the retinal capillaries in
diabetic retinopathy (senile and juvenile) - - with special
reference to the alteration in the basal lamina and the
pericytes. Nippon Ganka Galdmi Zasshi 79: 117-129.
Kojima, K., Matsubara, H., Harada, T., Mizuno, K., Suzuki, M.,

Aldose Reductase and Diabetic Retinopathy
Hotta, N., Kakuta, H. and Sakamoto, N. (1985) Effects of
aldose reductase inhibitor on retinal microangiopathy in
streptozotocin-diabetic rats. Jap. J. Ophthal. 29: 99-109.
Kroc Collaborative Study Group (1984) Blood glucose control
and the evolution of diabetic retinopathy and albuminuria.
A preliminary multicenter trial. New Engl. J. Med. 311:
365-372.
Krolewski, A. S., Warram, J. H., Rand, L. I. and Kahn, C. R.
(1987) Epidemiologic approach to the etiology of type I
diabetes mellitus and its complications. New Engl. J. Med.
317: 1390-1398.
Kuwabara, T. and Cogan, D. G. (1960) Studies of retinal vascular
patterns. Part I. Normal architecture. Archs Ophthal. 64:
904-911.
Knwabara, T. and Cogan, D. G. (1963) Retinal vascular patterns.
VI. Mural cells of the retinal capillaries. Archs Ophthal.
69: 492-502.
Kuwabara, T. and Cogan, D. G. (1965) Retinal vascular patterns.
VII. AceUular change. Invest. Ophthalmol. Vis. Sci. 4:
1049-1058.
Kuwabara, T., Carroll, J. M. and Cogan, D. G. (1961) Retinal
vascular patterns. III. Age, hypertension, absolute
glaucoma, injury. Archs Ophthal. 65: 708-716.
L'Esperance, F. Jr (1989) In: Ophthalmic Lasers Third Edition.
Vol 1. C. V. Mosby Company, St Louis, Missouri.
Laver, N. M. and Robison, W. G. Jr (1993) Proliferative
retinopathy stage in long-term galactose fed rats. Invest.
Ophthalmol. Vis. Sci. 34 (Suppl.): 713.
Laver, N. M., Robison, W. G. Jr and Hansen, B. C. (1994)
Spontaneously diabetic monkeys as a model for diabetic
retinopathy. Invest. Ophthalmol. Vis. Sci. 35 (Suppl.):
1733.
Laver, N. M., Robison, W. G. Jr and Pfeffer, B. A. (1993) Novel
procedures for isolating intact retinal vascular beds from
diabetic humans and animal models. Invest. Ophthalmol.
Vis. Sci. 34: 2097-2104.
Lee, M. and Sarvetnick, N. (1993) Transgeuic animal:
contributions of transgenic constructs to the etiology and
pathogenesis of diabetes. In: Lessons from Animal Diabetes
IV, Biennial Review. (E. Shafrir, ed.) pp. 241-246. Vol.
1992. Smith-Gordon and Company Limited, London.
Lee, A. Y. W., Chung, S. K. and Chtmg, S. S. M. (1995)
Transgenic mice expressing the aldose reductase gene in
the lens showed that polyol accumulation is responsible for
diabetic cataract. (in press).
Little, H. L. (1976) The role of abnormal hemorrheodynamies in
the pathogenesis of diabetic retinopathy. Trans. Am.
ophthal. Soc. 74: 573-636.
Lutty, G. A., McLcod, D. S., Paehnis, A., Costantini, F., Fabry,
M. E. and Nagel, R. L. (1994) Retinal and choroidal
neovaseularization in a transgenic mouse model of sickle
cell disease. Am. J. Path. 145: 490-497.
Macleod, A. F., Boulton, A. J. M., Owens, D. R., Van Rooy, P.,
Van Gerven, J. M. A., Macrnry, S., Searpello, J. H. B.,
Segers, O., HeUer, S. R., Van Der Veen, E. A. and North
European Tolrestat Study Group (1992) A multicentre trial
of the aldose-reductase inhibitor tolrestat, in patients with

637

symptomatic diabetic peripheral neuropathy. Diab. Metab.
18: 14-20.
Magnire, A. M. and Schachat, A. P. (1994) Radiation retinopathy.
In: Retina, Volume 2: Medical Retina (S. J. Ryan, A. P.
Schachat and R. B. Murphy, eds) pp. 1509-1514. C. V.
Mosby Company, St Louis, Missouri.
Mandarino, L. J., Finlayson, J. and Hassell, J. R. (1994) High
glucose downregnlates glucose transport activity in retinal
capillary pericytes but not endothelial cells. Invest.
Ophthalmol. Vis. Sci. 35: 964-972.
Mansour, A. M., Rodenko, G. and Dutt, R. (1990a) Half-life of
cotton-wool spots in the acquired immunodeficiency
syndrome. Int. J. STD / AIDS 1: 132-133.
Mansour, S. Z., Hatchell, D. L., Chandler, D., Saloupis, P. and
Hatchell, M. C. (1990b) Reduction of basement membrane
thickening in diabetic cat retina by sulindac. Invest.
Ophthalmol. Vis. Sci. 31: 457---463.
McCaleb, M. L., McKean, M. L., Hohman, T. C., Laver, N. and
Robison Jr, W. G. (1991) Intervention with the aldose
reductase inhibitor, tokestat, in renal and retinal lesions of
streptozotocin-diabetic rats. Diabetologia 34- 695-701.
Mcl.eod, D., Marshall, J., Kohner, E. M. and Bird, A. C. (1977)
The role of axoplasmic transport in the pathogenesis of
retinal cotton-wool spots. Br. J. OphthaL 61: 177-191.
Michaelis, I. V., O. E., Carswell, N., Hansen, C. T., Canary, J. J.
and Kimmel, P. L. (1988) A new genetic model of
nouinsulin-dependent diabetes and hypertension: the
spontaneous hypertensive/NIH corpulent rat. In: Frontiers
in Diabetes Research. Lessons from Animal Diabetes II (E.
E. Shafrir and A. E. Renold, eds) pp. 257-264. John
Libbey and Company Ltd, New York.
Michaelson, I. C. (1948) The mode of development of the vascular
system of the retina, with some observations on its
significance for certain retinal diseases. Trans. ophthal.
Soc. U.K 68: 137-180.
Michaelson, I. C. (1980) In: Textbook of the Fundns of the Eye.
Churchill Livingstone, London.
Miller, F. N. and Sims, D. E. (1986) Contractile elements in the
regulation of macromolecular permeability. Fedn Proc.
45: 84-88.
Moil, Y., Yokoyama, J., Nishimura, M. and Ikeda, Y. (1991)
Diabetes in WBN/KOB rats. In: Diabetes 1991:
Proceedings of the 14th International Diabetes Federation
Congress. Washington DC, 23-28 June 1991 (H. RiIkin, J.
A. Colwell and S. I. Taylor, eds) pp. 595-598. Elsevier
Science Publishers BV, Amsterdam.
Nagaraj, R. H. and Monuier, V. M. (1992) Isolation and
characterization of a blue fluorophore from human eye
lens crystallins: in vitro formation from Malllard reaction
with ascorbate and ribose. Biochim. biophys. Acta 1116:
34-42.
Nagaraj, R. H., Prabhakaram, M., Ortwerth, B. J. and Monnier, V.
M. (1994) Suppression of pentosidine formation in
galactosemic rat lens by an inhibitor of aldo~e reductase.
Diabetes 43: 580-586.
Nagaraj, R. H., Sell, D. R., Prabhakaram, M., Ortwerth, B. J. and
Monuier, V. M. (1991) High correlation between

638

W. G. Robison et al.

pentosidine protein crosslinks and pigmentation implicates
ascorbate oxidation in human lens senescene and
cataractogenesis. Proc. natn. Acad. Sci. U.S.A. 88: 1025710261.
National Advisory Eye Council (1977) In: Vision Research. A
National Plan: 1978-1982. Vol. 1. Summary, DHEW
Publ. No. (NIH) 78-1258' National Institutes of Health,
Bethesda, MD.
Nishimura, C., Akagi, Y., Robison, W. G. Jr, Kador, P. F. and
Kinoshita, J. H. (1988a) Increased aldose reductase activity
in galactosemic lens. In: Polyol Pathway and Its Role in
Diabetic Complications (N. Sakamoto, J. H. Kinoshita, P.
F. Kador and N. Hotta, eds) pp. 182-188. Elsevier Science
Publishers BV (Biomedical Division), Netherlands.
Nishimura, C., Graham, C., Hohman, T. C., Nagata, M., Robison,
W. G. Jr and Carper, D. (1988b) Characterization of
mRNA and genes for aldose reductase in rat. Biochem.
biophys. Res. Commun. 153: 1051-1059.
Norton, E. W. D. and Gutman, F. (1967) Fluorescein angiography
of the retina in diabetes mellitus. In: Vascular
Complications of Diabetes Mellitns, with Special Emphasis
on Microangiopathy of the Eye (S. J. Kimura and W. M.
Caygill, eds) pp. 120-138. C. V. Mosby Company, St
Louis. Missouri.
Orlidge, A. and D'Amore, P. A. (1987) Inhibition of capillary
endothelial cell growth by pericytes and smooth muscle
cells. J. Cell Biol. 105: 1455-1462.
Palmer, E. A., Patz, A., Phelps, D. L. and Spencer, R. (1994)
Retinopathy of prematurity. In: Retina, Volume Two:
Medical Retina (S. J. Ryan, A. P. Schachat and R. B.
Murphy, eds) pp. 1473-1498. C. V. Mosby Company, St
Louis, Missouri.
Papachristodoulou, D. and Heath, H. (1977) Ultrastructural
alterations during the development of retinopathy in
sucrose-fed and streptozotocin-diabetic rats. Expl Eye Res.
25: 371-384.
Papachristodoulou, D., Heath, H. and Kang, S. S. (1976) The
development of retinopathy in sucrose-fed and
streptozotocin-diabetic rats. Diabetologia 12: 367-374.
Patz, A. (1984) Retinal neovaseularisation: early contributions of
Professor Michaelson and recent observations. Br. J.
Ophthal. 68: 42-46.
Pat,z, A. and Fine, S. L. (1977) Observations in diabetic macular
edema. In: Symposium on Retinal Diseases, Transactions
of the New Orleans Academy of Ophthalmology (M. D.
Davis, ed.) pp. 101-115. C. V. Mosby Company, St Louis,
Missouri.
Patz, A. and Maumenee, A. E. (1962) Studies on diabetic
retinopathy, I. Retinopathy in a dog with spontaneous
diabetes mellitus. Ant J. Ophthal. 54: 532-541.
Patz, A., Berkow, J. W., Maumenee, A. E. and Cox, J. (1965)
Studies on diabetic retinopathy, II. Retinopathy and
nephropathy in spontaneous canine diabetes. Diabetes 14:
700-708.
Perry, R. E., Swamy, M. S. and Abraham, E. C. (1987) Progressive
changes in lens crystallin glycation and high-molecularweight aggregate formation leading to cataract development
in streptozotocin-diabetic rats. Expl Eye Res. 44: 269-282.

Petersen, M. R., Vine, A. IC and The University of Michigan
Pancreas Transplant Evaluation Committee (1990)
Progression of diabetic retinopathy after pancreas
transplantation. Ophthalmology 97: 496-502.
Poulsen, J. E. (1953) Recovery from retinopathy in a case of
diabetes with Simmonds' disease. Diabetes 2: 7-11.
Reichard, P., Nilsson, B. Y. and Rosenqvist, U. (1993) The effect
of long-term intensified insulin treatment on the
development of microvascular complications of diabetes
mellitus. New Engl. J. Med. 329: 304-309.
Reinecke, R. D., Kuwabara, T., Cogan, D. G. and Weis, D. R.
(1962) Retinal vascular patterns. Part V: experimental
ischemia of the cat eye. Archs Ophthal. 67: 470-475.
Reiser, H. J., Whitworth, U. G. Jr, Hatchell, D. L., Sutherland, F.
S., Nanda, S., McAdoo, T. and Hardin, J. R. (1987)
Experimental diabetes in cats induced by partial
pancreatectomy alone or combined with local injection of
alloxan. Lab. Anita. Sci. 37: 449-452.
Robison, W. G. Jr (1994) Aldose reductase inhibition and
retinopathy. Diabetes 43: 337-338.
Robison, W. G. Jr and Laver, N. M. (1993) Ocular lesions in
animal models of human diabetes. In: Lessons from Animal
Diabetesl-V, BienniaiReview (E. Shafrir, ed.) pp. 145-163.
Vol. 1992. Smith-Gordon and Company Limited, London.
Robison, W. G. Jr and Laver, N. M. (1994) Sorbinil prevention of
cataracts and retinopathy in the gslactose-fed rat model of
diabetic complications. Invest. Ophthalmol. Via. Sci. 35
(Suppl.): 1586.
Robison, W. G. Jr and Nagata, M. (1988) Aldose reductase in
mural cell loss and retinal capillary basement membrane
thickening. In: Polyol Pathway and Its Role in Diabetic
Complications (N. Sskamoto, J. H. Kinoshita, P. F. Kador
and N. Hotta, eds) pp. 267-275. Elsevier Science
Publishers BV (Biomedical Division), Netherlands.
Robison, W. G. Jr, Holder, N. and Kinoshita, J. H. (1990a) The
role of lens epithelium in sugar cataract formation. F.~l
Eye Res. S0: 641-646.
Robison, W. G. Jr, Holder, N., Laver, N., Lou, M. and Kinoshita,
J. H. (1990b) The role of lens epithelium in sugar cataracts.
Invest. Ophthalmol. VIS. Sci. 31 (Suppl.): 346.
Robison, W. G. Jr, Kador, P. F., Akagi, Y., Kinoshita, J. H.,
Gonzalez, R. and Dvornik, D. (1986) Prevention of
basement membrane thickening in retinal capillaries by a
novel inhibitor of aldose reductase, tolrestat. Diabetes 35:
295-299.
Robison, W. (3. Jr, Kador, P. F. and Kinoshita, J. H. (1983)
Retinal capillaries: basement membrane thickening by
galactosemia prevented with aldose reductase inhibitor.
Science (USA) 221: 1177-1179.
Robison, W. ¢3. Jr, Laver, N. and Kador, P. F. (1992) Meager
delay of sugar cataracts and pre-proliferative retinopathy in
galactose-fed rats by the ARI ponalrestat. Invest.
Ophthalmol. VIS. Sci. 33 (Suppl.): 878.
Robison, W. t3. Jr, Laver, N. M. and Kinoshita, J. H. (1991a)
Galactosemic rat model for diabetic retinopathy: prevention
of capillary dilations, microaneurysms, aceUularity, and
shunt meshworks with aldose roductase inhibitors. In:
Aldase Reductase Inhibitors. N-El-Juvenile Diabetes

Aldose Reductase and Diabetic Retinopathy
Foundation Workshop NIH Publ #91-3114 (National Eye
Institute and Juvenile Diabetes Foundation, eds) pp. 89100. National Institutes of Health, Bethesda, MD.
Robison, W. G. Jr, McCaleb, M. L., Feld, L. G., Michaelis, O. E.
IV, Laver, N. and Mercandetti, M. (1991b) Degenerated
intramural pericytes ('ghost cells') in the retinal capillaries
of diabetic rats. Curt. Eye Res. 10: 339-350.
Robison, W. G. Jr, Laver, N. M., York, B. M., Chandler, M. L.
and Lou, M. F. (1993) ARI intervention studies of galactose
induced retinopathy by computer analysis of retinal vessel
images. Invest. Ophthalmol. Vis. Sci. 34 (Suppl.): 718.
Robison, W. G. Jr, Nagata, M. and Kinoshita, J. H. (1988) Aldose
reductase and retinal capillary basement membrane
thickening. Expl Eye Res. 46: 343-348.
Robison, W. G. Jr, Nagata, M., Laver, N., Hohman, T. C. and
Kinoshita, J. H. (1989a) Diabetic-like retinopathy in rats
prevented with an aldose reductase inhibitor. Invest.
Ophthalmol. Vis. Sci. 30: 2285-2292.
Robison, W. G. Jr, Nagata, M., Tillis, T. N., Laver, N. and
Kinoshita, J. H. (1989b) Aldose reductase and pericyteendothelial cell contacts in retina and optic nerve. Invest.
Ophthalmol. Vis. ScL 30" 2293-2299.
Robison, W. G. Jr, Tillis, T. N., Laver, N. and Kinoshita, J. H.
(1990c) Diabetes-related histopathologies of the rat retina
prevented with an aldose reductase inhibitor. Expl Eye
Res. 50: 355-366.
Rosenmann, E., Yanko, L. and Cohen, A. M. (1975) Comparative
study of the pathology of sucrose-induced diabetes in the
rat and adult-onset diabetes in man. Israel J. Med. Sci. 11:
753-761.
Sahel, J. A., Brini, A. and Albert, D. M. (1994) Pathology of the
retina and vitreous. In: Principles and Practice of
Ophthalmology: Clinical Practice (D. M. Albert and F. A.
Jakobiec, eds) pp. 2239-2280. Vol. 4. W. B. Saunders
Company, Philadelphia, PA.
Santiago, J. V. (1992) Intensive management of insulin dependent
diabetes: risks, benefits, and unanswered questions. J.
Clin. Endocr. Metab. 75: 977-982.
Santiago, J. V., Srnksen, P. H., Boulton, A. J. M., Macleod, A.,
Beg, M., Bochenek, W., Graepel, G. J.; Gonen, B. and The
Tolrestat Study Group (1993) Withdrawal of the aldose
reductase inhibitor tolrestat in patients with diabetic
neuropathy: effect on nerve function. J. Diab. Comp. 7:
170-178.
Sato, S., Takahashi, Y., Wyman, M. and Kador, P. F. (1991)
Progression of sugar cataract in the dog. Invest.
Ophthalmol. Vis. Sci. 32: 1925-1931.
Seddon, J. M., Christen, W. G., Manson, J. E., Buring, J. E.,
Sperduto, R. D. and Hennekens, C. H. (1991) Low-dose
aspirin and risks of cataract in randomized trial of US
physicians. Archs Ophthal. 109: 252-255.
Shafrir, E. (1993) In: Lessons from Animal Diabetes IV, Biennial
Review. Vol. 1992. Smith-Gordon and Company Limited,
London.
Shimizu, K., Kobayashi, Y. and Muraoka, K. (1981) Midperipheral
fundus involvement in diabetic retinopathy. Ophthalmology
88: 601-612.
Sibay, T. M. and Hausler, H. R. (1967) Eye findings in two

639

spontaneously diabetic related dogs. Am. J. Ophthal. 63:
289-294.
Sima, A. A. F., Garcia-Salinas, R. and Basu, P. K. (1983) The BB
Wistar rat: an experimental model for the study of diabetic
retinopathy. Metabolism 32: 136-140.
Sima, A. A. F., Chakrabarti, S., Garcia-Salinas, R. and Basu, P.
K. (1985) The BB-rat - - an authentic model of human
diabetic retinopathy. Curr. Eye Res. 4: 1087-1092.
Sima, A. A. F., Greene, D. A., Brown, M. B., Hohman, T. C.,
Hicks, D., Graepel, G. J., Bochenek, W. J., Beg, M.,
Bonen, B. and The Tolrestat Study Group (1993) Effect of
hyperglycemia and the aldose reductase inhibitor tolrestat
on sural nerve biochemistry and morphometry in advanced
diabetic peripheral polyneuropathy. J. Diab. Comp. 7:
157-169.
Simfin, C. M., Naeser, P. and Eriksson, U. J. (1993) Increased
lenticular aldose reductase activity and high incidence of
congenital cataract in the offspring of diabetic rats. Acta
Ophthalraologica 71: 629-636.
Simard-Duquesne, N. and Dvornik, D. (1973) Galactitol
accumulation and irreversible lens opacities in galactosemic
rats. lnvest. OphthalraoL Vis. Sci. 12: 82-83.
Simard-Duquesne, N., Greselin, E., Gonzalez, R. and Dvornik, D.
(1985) Prevention of cataract development in severely
galactosemic rats by the aldose reductase inhibitor, tolrestat
(42048). Proc. Soc. exp. Biol. Med. 178: 599-605.
Sims, D. E. (1991) Recent advances in pericyte biology - Implications for health and disease. Can. J. Card. 7:
431-443.
Sims, D. E., Miller, F. N., Donald, A. and Perricone, M. A.
(1990) Ultrastructure of pericytes in early stages of
histamine-induced inflammation. J. Morph. 206: 333-342.
Sorbinil Retinopathy Trial Research Group (1990) A randomized
trial of sorbinil, an aldose reductase inhibitor, in diabetic
retinopathy. Archs Ophthal. 108: 1234-1244.
Speakman, J. S., Mortimer, C. B., Briant, T. D. R., Ezrin, C.,
Lougheed, W. M. and Clarke, W. T. W. (1966) Pituitary
ablation for diabetic retinopathy. Can. Med. Ass. J. 94:
627-635.
Speiser, P., Gittelsohn, A. M. and Patz, A. (1968) Studies on
diabetic retinopathy, III. Influence of diabetes on intramural
pericytes. Archs Ophthal. 80: 332-337.
Stefansson, E., Landers, M. B. HI and Wolbarsht, M. L. (1983)
Oxygenation and vasodilatation in relation to diabetic and
other proliferative retinopathies. Ophthal. Surg. 14: 209226.
Sternberg, M., Cohen-Forterre, L. and Peyroux, J. (1985)
Connective tissue in diabetes meUitus: biochemical
alterations of the intercellular matrix with special reference
to proteoglycans, collagens and basement membranes.
Diab. Metab. 11: 27-50.
Stewart, M. A., Kurien, M. M., Sherman, W. R. and Cotlier, E. V.
(1968) Inositol changes in nerve and lens of galactose fed
rats. J. Neurochera. 15: 941-946.
Stewart, T. A., Hultgren, B., Huang, X., Pitts-Meek, S., Hully, J.
and MacLachlan, N. J. (1993) Induction of type I diabetes
by interferon~ in transgenic mice. Science (USA) 260:
1942-1946.

640

W. G. Robison et al.

Stitt, A. W., Anderson, H. R., Gardiner, T. A. and Archer, D. B.
(1994) Diabetic retinopathy: quantitative variation in
capillary basement membrane thickening in arterial or
venous environments. Br. or. Ophthal. 78: 133-137.
Sugl, K. (1966) Studies on the pathological changes in the retinal
vessels of human eyes, using the trypsin digestion method.
Jap. J. Ophthal. 10: 252-266.
Sunderk~tter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R. and
Sorg, C. (1994) Macrophages and angiogenesis. J. Leuk.
Biol. 55: 410-422.
Swamy, M. S. and Abraham, E. C. (1989) Inhibition of lens
crystallin glycation and high molecular weight aggregate
formation by aspirin in vitro and in vivo. Invest.
Ophthalmol. Vis. ScL 30: 1120-1126.
Takahashi, Y., Wyman, M., Ferris, F. III and Kador, P. F. (1992)
Diabetes-like preproliferative retinal changes in galactosefed dogs. Archs Ophthal. 110: 1295-1302.
Takahashi, Y., Augustin, W., Wyman, M. and Kador, P. F. (1993)
Quantitative analysis of retinal vessel changes in
galactose-fed dogs. J. Ocular Pharmac. 9: 257-269.
Taylor, E. and Dobree, J. H. (1970) Proliferative diabetic
retinopathy, site and size of initial lesions. Br. J. Ophthal.
54: 11-18.
Triton, R. G., I.aRose, L. S., Kilo, C. and Williamson, J. R.
(1986) Absence of degenerative changes in retinal and
uveal capillary pericytes in diabetic rats. Invest.
Ophthalmol. Vis. Sci. 27: 716-721.
Tilton, R. G., Chang, IC, Hasan, K. S., Smith, S. R., Petrash, J.
M., Misko, T. P., Moore, W. M., Currie, M. G., Corbett, J.
A., McDaniel, M. L. and Williamson, J. R. (1993)
Prevention of diabetic vascular dysfunction by guanidines.
Inhibition of nitric oxide synthase versus advanced
glycation end-product formation. Diabetes 42: 221-232.
Tonssaint, D. (1968) Contribution ~t l'6tude anatomique et clinique
de la r6tinopathie diab6tique chez l'homme et chez
l'animal. Pathol. Europ. 3: 11-167.
Toussalnt, D. and Dustin, P. (1963) Electron microscopy of
normal and diabetic retinal capillaries. Archs Ophthal. 70:
140-152.
Varma, S. D. and Kinoshita, J. H. (1974) The absence of cataracts
in mice with congenital hyperglycemia. Expl Eye Res. 19:
577-582.
Varma, S. D., Mizuno, A. and Kinoshita, J. H. (1977) Diabetic
cataracts and flavonoids. Science (USA) 195: 205-206.
Wallow, I. H. L., Bindiey, C. D., Linton, ~ L. P. and Rastegar,
D. (1991) Pericyte changes in branch retinal vein occlusion.
Invest. OphthalmoL Vis. Sci. 32: 1455-1463.
Warram, J. H., Rich, S. S. and Krolewski, A. S. (1994)

Epidemiology and genetics of diabetes mellitus. In: Joslin's
Diabetes Mellitus (C. R. Kahn and G. C. Weir, eds) pp.
201-215. Lea and Febiger, Philadelphia, PA.
Weinberg, D. V. and Seddon, J. M. (1994) Venous occlusive
diseases of the retina. In: Principles and Practice of
Ophthalmology, Clinical Practice (D. M. Albert and F. A.
Jakobiec, eds) pp. 735-746. Vol. 2. W. B. Saunders
Company, Philadelphia, PA.
White, P. (1960) Childhood diabetes. Its course, and influence on
the second and third generations. The Banting Memorial
Lecture 1960. Diabetes 9: 345-355.
Williamson, J. R. and Kilo, C. (1977) Current status of capillary
basement-membrane disease in diabetes mellitus. Diabetes
26: 65-73.
Williamson, J. R., Chang, K., Frangos, M., Hasan, K. S., Ido, Y.,
Kawamura, T., Nyengaard, J. R., van den Enden, M., Kilo,
C. and Triton, R. G. (1993) Hyperglycemic pseudohypoxia
and diabetic complications. Diabetes 42: 801-813.
Winter, F. C. (1960) Diabetic retinopathy, degenerative vascular
complications of diabetes and discussion of clinical aspects
of the disease. J. Am. meg Ass. 174: 143-146.
Wise, G. N. (1957) Retinal neovascdarization. In: Transactions of
the American Ophthalmological Society pp. 729-826.
Columbia University Press, New York.
Wolter, J. R. (1959) Pathology of a cotton-wool spot. Am. J.
Ophthal. 48: 473-485.
Wolter, J. R. (1961) Diabetic capillary microaneurysms of the
retina. Archs Ophthal. 65: 107-114.
Yanko, L., Michaelson, I. C. and Cohen, A. M. (1971) The
retinopathy of sucrose-fed rats. In: Causes and Prevention
of Blindness, Proceedings of the Jerusalem Seminar on the
Prevention of Blindness, 2 5 - 2 7 August 1971 (L C.
Michaelson and E. R. Berman, eds) pp. 612-616.
Academic Press, New York.
Yanko, L., Rosenmann, E. and Cohen, A. M. (1975) A correlative
study on the occurrence of retinopathy and nephropathy in
sucrose-fed diabetic rats. Acta Diabet. 12: 52-65.
Yanoff, M. (1966) Diabetic retinopathy. New Engl. J. Med. 274:
1344-1349.
Yanoff, M. (1969) Ocular pathology of diabetes mellitas. Am. J.
Ophthal. 67: 21-38.
Yue, D. K., Hanweli, M. A., Satcbell, P. M., Handelsman, D. J.
and Turtle, J. R. (1984) The effects of aldose reductase
inhibition on nerve sorbitol and myo-inositol concentrations
in diabetic and galactosemic rats. Metabolism 33: 11191122.
Zinman, B. (1989) The physiologic replacement of insulin. New
Engl. J. Med. 321: 363-370.

